INN_Name,BrandName,Phase,Applicants,LigID,pdbID,Type,RoF,MW,LogP,TPSA,HBA,HBD,NRB,Indications,Targets,Kinase families,Canonical_Smiles_InChiKey,First_Approval,SC_Patent,Chirality,Synonyms,FDA approved,Melting points (°C),Image URL
Abemaciclib,Verzenio,4,Eli Lilly,'6ZV',5l2s,1,1,506.3,4.9,75,8,1,7,"On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","CDK4
CDK6",CMGC,"Smiles=CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(c(n3)c4cc5c(c(c4)F)nc(n5C(C)C)C)F
InChiKey=UZWDCWONPYILKI-UHFFFAOYSA-N",2017,US-7855211-B2,Achiral Molecule,"Verzenio
Abemaciclib
LY-2835219",Y,,www.icoa.fr/pkidb/static/img/mol/Abemaciclib.svg
Abivertinib,nan,3,ACEA Biosciences,NaN,NaN,nan,0,487.2,4.5,98.4,7,3,7,"AC0010 is an orally active, irreversible EGFR inhibitor that selectively targets mutated EGFRs, and was designed to overcome T790M-induced resistance in tumours [2]. It may also inhibit BTK, thus offering extended clinical utility [3]. We show the structure for the free base form of the compound.",nan,,"Smiles=CN1CCN(CC1)c2ccc(cc2F)Nc3nc4c(cc[nH]4)c(n3)Oc5cccc(c5)NC(=O)C=C
InChiKey=UOFYSRZSLXWIQB-UHFFFAOYSA-N",nan,nan,nan,"AC0010
Avitinib",,,www.icoa.fr/pkidb/static/img/mol/Abivertinib.svg
Acalabrutinib,Calquence,4,Astrazeneca,NaN,NaN,nan,0,465.2,3.3,118.5,7,2,4,Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy,BTK,Tyr,"Smiles=CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5
InChiKey=WDENQIQQYWYTPO-IBGZPJMESA-N",2017,US-9290504-B2,Single Stereoisomer,"Calquence
ACP-196
Acalabrutinib",Y,,www.icoa.fr/pkidb/static/img/mol/Acalabrutinib.svg
Acalisib,nan,2,Gilead Sciences,NaN,NaN,nan,0,401.1,3.4,101.4,7,2,4,nan,PIK3CA,Atypical,"Smiles=C[C@@H](c1nc2ccc(cc2c(=O)n1c3ccccc3)F)Nc4c5c(nc[nH]5)ncn4
InChiKey=DOCINCLJNAXZQF-LBPRGKRZSA-N",nan,nan,Single Stereoisomer,CAL-120,,,www.icoa.fr/pkidb/static/img/mol/Acalisib.svg
Acumapimod,nan,2,Mereo BioPharma,NaN,NaN,nan,0,385.2,2.8,113.8,6,2,5,nan,"MAPK14
MAPK11
MAPK13
MAPK12",CMGC,"Smiles=Cc1ccc(cc1n2c(c(cn2)C(=O)c3cccc(c3)C#N)N)C(=O)NC4CC4
InChiKey=VGUSQKZDZHAAEE-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,,,,www.icoa.fr/pkidb/static/img/mol/Acumapimod.svg
Adavosertib,nan,2,Astrazeneca,'8X7',5v5y 5vd0 5vdk,1,1,500.3,2.9,104.3,10,2,7,nan,WEE1,Other,"Smiles=CC(C)(c1cccc(n1)n2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)c(=O)n2CC=C)O
InChiKey=BKWJAKQVGHWELA-UHFFFAOYSA-N",nan,nan,nan,"AZD-1775
MK-1775",,,www.icoa.fr/pkidb/static/img/mol/Adavosertib.svg
Afatinib,Gilotrif,4,Boehringer Ingelheim,'0WM',4g5j,1,0,485.2,4.4,88.6,7,2,8,Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.,"EGFR
ERBB2
ERBB4",Tyr,"Smiles=CN(C)C/C=C/C(=O)Nc1cc2c(cc1O[C@H]3CCOC3)ncnc2Nc4ccc(c(c4)Cl)F
InChiKey=ULXXDDBFHOBEHA-CWDCEQMOSA-N",2013,US-6251912-B1,Single Stereoisomer,"Giotrif;Gilotrif
Afatinib
BIBW-2992",Y,,www.icoa.fr/pkidb/static/img/mol/Afatinib.svg
Afuresertib,nan,2,GlaxoSmithKline,NaN,NaN,nan,0,426,3.9,72.9,5,2,6,nan,"AKT1
AKT2
AKT3",AGC,"Smiles=Cn1c(c(cn1)Cl)c2cc(sc2Cl)C(=O)N[C@@H](Cc3cccc(c3)F)CN
InChiKey=AFJRDFWMXUECEW-LBPRGKRZSA-N",nan,nan,Single Stereoisomer,"GSK2110183
Afuresertib
GSK2110183C",,,www.icoa.fr/pkidb/static/img/mol/Afuresertib.svg
Alectinib,Alecensa,4,Hoffmann-La Roche,'EMH',3aox 5xv7,1,0,482.3,4.8,72.4,5,1,3,"Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",ALK,Tyr,"Smiles=CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C
InChiKey=KDGFLJKFZUIJMX-UHFFFAOYSA-N",2015,US-9126931-B2,Achiral Molecule,"Alectinib
CH-5424802
AF-802",Y,,www.icoa.fr/pkidb/static/img/mol/Alectinib.svg
Alisertib,nan,3,Millennium Pharmaceuticals,'A5B',5ia0,1,2,518.1,5.7,105.9,7,2,6,For the treatment of various forms of cancer.,AURKA,Other,"Smiles=COc1cccc(c1C2=NCc3cnc(nc3-c4c2cc(cc4)Cl)Nc5ccc(c(c5)OC)C(=O)O)F
InChiKey=ZLHFILGSQDJULK-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MLN-8237
Alisertib",,,www.icoa.fr/pkidb/static/img/mol/Alisertib.svg
Allitinib,nan,1,Allist Pharmaceuticals,NaN,NaN,nan,1,448.1,5.9,76.1,5,2,7,nan,"ERBB2
EGFR",Tyr,"Smiles=C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc3ccc(c(c3)Cl)OCc4cccc(c4)F
InChiKey=MVZGYPSXNDCANY-UHFFFAOYSA-N",nan,nan,nan,"AST-1306
ALL-3",,,www.icoa.fr/pkidb/static/img/mol/Allitinib.svg
,Piqray,4,Novartis,'1LT',4jps,nan,0,441.1,3.8,101.2,5,2,4,"On may 2019, FDA approved alpelisib to treat breast cancer",PIK3CA,Atypical,"Smiles=Cc1c(sc(n1)NC(=O)N2CCC[C@H]2C(=O)N)c3ccnc(c3)C(C)(C)C(F)(F)F
InChiKey=STUWGJZDJHPWGZ-LBPRGKRZSA-N",2019,nan,Single Stereoisomer,"NVP-BYL719
Alpelisib
BYL-719",Y,,www.icoa.fr/pkidb/static/img/mol/Alpelisib.svg
Altiratinib,nan,1,Deciphera Pharmaceuticals,NaN,NaN,nan,1,510.2,5,109.4,5,3,8,nan,"MET
TEK
KDR
NTRK1",Tyr,"Smiles=c1cc(ccc1NC(=O)C2(CC2)C(=O)Nc3cc(c(cc3F)Oc4ccnc(c4)NC(=O)C5CC5)F)F
InChiKey=GNNDEPIMDAZHRQ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"DCC-2701
Altiratinib
DP-5164",,,www.icoa.fr/pkidb/static/img/mol/Altiratinib.svg
Alvocidib,nan,3,Sanofi,'CPB',1c8k 1e1y 3blr 3ebp 4o71,nan,0,401.1,3.3,94.1,6,3,2,"Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).",nan,,"Smiles=CN1CC[C@@H]([C@@H](C1)O)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O
InChiKey=BIIVYFLTOXDAOV-YVEFUNNKSA-N",nan,nan,Single Stereoisomer,"L-86-8275
Flavopiridol
MDL-107826A
HL-275
HMR-1275
Alvocidib
NSC-649890
L-868275",,,www.icoa.fr/pkidb/static/img/mol/Alvocidib.svg
Amcasertib,nan,2,Boston Biomedical,NaN,NaN,nan,2,539.2,6,90.1,5,3,9,nan,PDGFRA,Tyr,"Smiles=CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)c4csc(n4)c5ccccc5)C
InChiKey=QDWKGEFGLQMDAM-ULJHMMPZSA-N",nan,nan,Achiral Molecule,"BBI-503
Amcasertib",,,www.icoa.fr/pkidb/static/img/mol/Amcasertib.svg
Amuvatinib,nan,2,Supergen,NaN,NaN,nan,0,447.1,3.3,75.9,7,1,3,"Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical comp\nonent of double-stranded DNA repair in cancer cells.","KIT
MET
RET
FLT3
PDGFRB",Tyr,"Smiles=c1ccc2c(c1)c3c(o2)c(ncn3)N4CCN(CC4)C(=S)NCc5ccc6c(c5)OCO6
InChiKey=FOFDIMHVKGYHRU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MP-470
HPK56
Amuvatinib
HPK-56",,,www.icoa.fr/pkidb/static/img/mol/Amuvatinib.svg
Anlotinib,nan,4,Advenchen Laboratories,NaN,NaN,nan,0,407.2,4.8,82.4,5,2,6,"Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID: 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123.","KDR
FLT4",Tyr,"Smiles=Cc1cc2c([nH]1)ccc(c2F)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC
InChiKey=KSMZEXLVHXZPEF-UHFFFAOYSA-N",nan,nan,nan,"ALTN

APCII
AL3818
ATC I
FU KE WEI
APC I
ATCII
ANLOTINIB",N,,www.icoa.fr/pkidb/static/img/mol/Anlotinib.svg
Apatinib,nan,4,Bukwang Pharmaceutical,NaN,NaN,nan,1,397.2,5.1,90.7,5,2,5,"Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.",KDR,Tyr,"Smiles=N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1Nc1cnccc1C
InChiKey=MGZNERAVOCFMCU-UHFFFAOYSA-N",2014,nan,nan,"NO.
STUDY DRUG
5-FLUOROURACIL
VP-16
ALBUMIN PACLITAXEL
AITAN
DOCETAXEL
EGAFUR
EMOZOLOMIDE（TMZ）
PLATINU
NAVELBINE+AITAN
PEMETREXED
H20140103
S1
ARGET THERAPY
SPA
YN968D1
CARBOPLATIN
ARM A
PACLITAXOL
XELOX
APATINIB GROUP
S-1
ATAN
AI TAN
APATINIB
REATMENT GROUP
CAPECITABINE
YEW
APATINIB MESYLATE
ESYLATE APATINIB
APATINIB TABLETS
OXALIPLATIN
YN968D1,(AITAN®",N,,www.icoa.fr/pkidb/static/img/mol/Apatinib.svg
Apitolisib,nan,2,Hoffmann-La Roche,'980',3tl5,nan,1,498.2,0.9,133.8,11,2,5,nan,"PIK3CA
MTOR",Atypical,"Smiles=Cc1c(sc2c1nc(nc2N3CCOCC3)c4cnc(nc4)N)CN5CCN(CC5)C(=O)[C@H](C)O
InChiKey=YOVVNQKCSKSHKT-HNNXBMFYSA-N",nan,nan,Single Stereoisomer,"GDC-0980.1
RG-7422
G-038390.1
GDC-0980
Apitolisib
G-038390",,,www.icoa.fr/pkidb/static/img/mol/Apitolisib.svg
Asciminib,nan,3,Novartis,'AY7',5mo4,nan,0,449.1,3.5,103.4,6,3,6,nan,nan,,"Smiles=c1cc(ccc1NC(=O)c2cc(c(nc2)N3CC[C@H](C3)O)c4ccn[nH]4)OC(F)(F)Cl
InChiKey=VOVZXURTCKPRDQ-CQSZACIVSA-N",nan,nan,nan,ASCIMINIB,,,www.icoa.fr/pkidb/static/img/mol/Asciminib.svg
Avapritinib,nan,3,Blueprint Medicines,NaN,NaN,nan,0,498.2,2.6,106.3,10,1,5,nan,nan,,"Smiles=C[C@](c1ccc(cc1)F)(c2cnc(nc2)N3CCN(CC3)c4c5cc(cn5ncn4)c6cnn(c6)C)N
InChiKey=DWYRIWUZIJHQKQ-SANMLTNESA-N",nan,nan,nan,BLU-285,,,www.icoa.fr/pkidb/static/img/mol/Avapritinib.svg
Axitinib,Inlyta,4,Pfizer,'AXI',4ag8 4agc 4twp 4wa9,2,0,386.1,4.6,70.7,4,2,5,Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.,"FLT1
KDR
FLT4",Tyr,"Smiles=CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4
InChiKey=RITAVMQDGBJQJZ-FMIVXFBMSA-N",2012,US-6534524-B1,Achiral Molecule,"Inlyta
AG-13736
Axitinib
AG-013736",Y,,www.icoa.fr/pkidb/static/img/mol/Axitinib.svg
Bafetinib,nan,2,Innovive Pharmaceuticals,'406',2e2b,2,2,576.3,5.4,99.2,8,2,8,nan,"LYN
ABL1",Tyr,"Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cncnc3)NC(=O)c4ccc(c(c4)C(F)(F)F)CN5CC[C@@H](C5)N(C)C
InChiKey=ZGBAJMQHJDFTQJ-DEOSSOPVSA-N",nan,nan,Single Stereoisomer,"CNS-9
Bafetinib
NS-187
INNO-406",,,www.icoa.fr/pkidb/static/img/mol/Bafetinib.svg
Balamapimod,nan,1,Wyeth,NaN,NaN,nan,2,573.2,6.5,82.2,9,1,7,nan,"RAF1
MAP2K1
MAP2K2","TKL
STE","Smiles=Cn1ccnc1Sc2ccc(cc2Cl)Nc3c4cc(c(cc4ncc3C#N)N5CCC(CC5)N6CCCC6)OC
InChiKey=CVAKNHIXTWLGJO-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MKI-833
Balamapimod",,,www.icoa.fr/pkidb/static/img/mol/Balamapimod.svg
Barasertib,nan,3,Astrazeneca,NaN,NaN,nan,1,587.2,3.6,174.8,9,5,15,nan,AURKB,Other,"Smiles=CCN(CCCOc1ccc2c(c1)ncnc2Nc3cc(n[nH]3)CC(=O)Nc4cccc(c4)F)CCOP(=O)(O)O
InChiKey=GBJVVSCPOBPEIT-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Barasertib
AZD-1152",,,www.icoa.fr/pkidb/static/img/mol/Barasertib.svg
Baricitinib,Olumiant,4,Eli Lilly,'3JW',4w9x,1,0,371.1,1.1,120.6,7,1,5,"Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.","JAK1
JAK2",Tyr,"Smiles=CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3
InChiKey=XUZMWHLSFXCVMG-UHFFFAOYSA-N",2017,nan,Achiral Molecule,"Baricitinib
LY-3009104
INCB-28050
INCB-028050",Y,,www.icoa.fr/pkidb/static/img/mol/Baricitinib.svg
Bemcentinib,nan,2,BerGenBio,NaN,NaN,nan,1,506.3,4.9,97.8,8,2,4,nan,AXL,Tyr,"Smiles=c1ccc-2c(c1)CCCc3c2nnc(c3)n4c(nc(n4)Nc5ccc6c(c5)CC[C@H](CC6)N7CCCC7)N
InChiKey=KXMZDGSRSGHMMK-VWLOTQADSA-N",nan,nan,nan,"BGB324; KEYTRUDA

BEMCENTINIB",,,www.icoa.fr/pkidb/static/img/mol/Bemcentinib.svg
Bentamapimod,nan,2,PregLem,NaN,NaN,nan,0,457.2,4.2,84.2,8,0,7,nan,"MAPK8
MAPK9",CMGC,"Smiles=N#CC(c1nc2ccccc2s1)c5nc(OCc3ccc(cc3)CN4CCOCC4)ncc5
InChiKey=XCPPIJCBCWUBNT-UHFFFAOYSA-N",nan,nan,Racemic Mixture,"PGL-5001
Bentamapimod
AS-602801",,,www.icoa.fr/pkidb/static/img/mol/Bentamapimod.svg
Berzosertib,nan,2,Vertex Pharmaceuticals,NaN,NaN,nan,0,463.2,3.9,124,8,2,7,nan,nan,,"Smiles=CC(C)S(=O)(=O)c1ccc(cc1)c2cnc(c(n2)c3cc(no3)c4ccc(cc4)CNC)N
InChiKey=JZCWLJDSIRUGIN-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"VX-970
Berzosertib",,,www.icoa.fr/pkidb/static/img/mol/Berzosertib.svg
Bimiralisib,nan,2,Piqur Therapeutics,'A3W',5oq4,nan,0,411.2,1,103.2,8,2,3,"Bimiralisib (PQR309) is a novel dual inhibitor of phosphoinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected utility as an anti-cancer agent.",nan,,"Smiles=c1c(c(c[nH]c1=N)c2nc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F
InChiKey=ADGGYDAFIHSYFI-UHFFFAOYSA-N",nan,nan,nan,"PQR309
BIMIRALISIB",,,www.icoa.fr/pkidb/static/img/mol/Bimiralisib.svg
Binimetinib,Mektovi,4,Novartis,NaN,NaN,nan,0,440,3,88.4,6,3,6,"On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",MAP2K1,STE,"Smiles=Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3F)Br)C(=O)NOCCO
InChiKey=ACWZRVQXLIRSDF-UHFFFAOYSA-N",2018,nan,Achiral Molecule,"ARRY-162
NVP-MEK162
Binimetinib
MEK-162
ARRY-438162",Y,,www.icoa.fr/pkidb/static/img/mol/Binimetinib.svg
Bosutinib,Bosulif,4,Wyeth,'DB8',3soa 3ue4 4mxo 4mxx 4mxy 4mxz 4qmn 5ajq 5i9x 5vc3 5vcy 6fdy 6op9,1,2,529.2,5.2,82.9,8,1,9,"Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.","BCR
ABL1
LYN
HCK
SRC
CDK2
MAP2K1
MAP2K2
MAP3K2
CAMK2G","Atypical
Tyr
STE
CAMK
CMGC","Smiles=CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC
InChiKey=UBPYILGKFZZVDX-UHFFFAOYSA-N",2012,US-6002008-A,Achiral Molecule,"Bosulif
Bosutinib Monohydrate
Bosutinib
SKI-606",Y,,www.icoa.fr/pkidb/static/img/mol/Bosutinib.svg
Brigatinib,Alunbrig,4,Ariad Pharmaceuticals,'6GY',6mx8,1,2,583.3,5.1,85.9,9,2,8,"The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.","ALK
EGFR",Tyr,"Smiles=CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(n4)Nc5ccccc5P(=O)(C)C)Cl
InChiKey=AILRADAXUVEEIR-UHFFFAOYSA-N",2017,US-9012462-B2,Achiral Molecule,"Alunbrig
AP-26113
Brigatinib",Y,,www.icoa.fr/pkidb/static/img/mol/Brigatinib.svg
Brivanib,nan,3,Bristol Myers Squibb,NaN,NaN,nan,0,370.1,3.5,84.7,6,2,5,nan,KDR,Tyr,"Smiles=Cc1cc2c([nH]1)ccc(c2F)Oc3c4c(c(cn4ncn3)OC[C@@H](C)O)C
InChiKey=WCWUXEGQKLTGDX-LLVKDONJSA-N",nan,nan,Single Stereoisomer,"Brivanib
BMS-540215",,,www.icoa.fr/pkidb/static/img/mol/Brivanib.svg
Buparlisib,nan,3,Novartis,'SD5',3sd5 5m7e,1,0,410.2,1.8,89.6,8,1,3,nan,PIK3CA,Atypical,"Smiles=c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F
InChiKey=CWHUFRVAEUJCEF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"NVP-BKM120
BKM-120
Buparlisib
BKM120-NX",,,www.icoa.fr/pkidb/static/img/mol/Buparlisib.svg
Cabozantinib,Cabometyx;Cometriq,4,Exelixis,NaN,NaN,2,2,501.2,5.5,98.8,6,2,8,For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.,"MET
KDR
RET",Tyr,"Smiles=COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F
InChiKey=ONIQOQHATWINJY-UHFFFAOYSA-N",2012,US-7579473-B2,Achiral Molecule,"Cabometyx;Cometriq
XL-184
Cabozantinib
BMS-907351",Y,,www.icoa.fr/pkidb/static/img/mol/Cabozantinib.svg
Canertinib,nan,3,Pfizer,NaN,NaN,nan,0,485.2,4.4,88.6,7,2,9,Investigated for use/treatment in breast cancer and lung cancer.,EGFR,Tyr,"Smiles=C=CC(=O)Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F
InChiKey=OMZCMEYTWSXEPZ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CI-1033
Canertinib",,,www.icoa.fr/pkidb/static/img/mol/Canertinib.svg
Capivasertib,nan,2,Astrazeneca,'0XZ',4gv1,nan,0,428.2,2.1,120.2,6,4,6,nan,AKT1,AGC,"Smiles=c1cc(ccc1[C@H](CCO)NC(=O)C2(CCN(CC2)c3c4cc[nH]c4ncn3)N)Cl
InChiKey=JDUBGYFRJFOXQC-KRWDZBQOSA-N",nan,nan,nan,AZD-5363,,,www.icoa.fr/pkidb/static/img/mol/Capivasertib.svg
Capmatinib,nan,3,Novartis,NaN,NaN,nan,0,412.1,3.4,85.1,6,1,4,nan,MET,Tyr,"Smiles=CNC(=O)c1ccc(cc1F)c2cnc3ncc(n3n2)Cc4ccc5c(c4)cccn5
InChiKey=LIOLIMKSCNQPLV-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"INC280
Capmatinib
INCB-28060
NVP-INC280
NYP-INC280-NX
INC-280",,,www.icoa.fr/pkidb/static/img/mol/Capmatinib.svg
Cediranib,Recentin,3,Astrazeneca,NaN,NaN,nan,1,450.2,5.2,72.5,6,1,8,"For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.",KDR,Tyr,"Smiles=Cc1cc2c([nH]1)ccc(c2F)Oc3c4cc(c(cc4ncn3)OCCCN5CCCC5)OC
InChiKey=XXJWYDDUDKYVKI-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Recentin
ZD-2171
AZD-2171
Cediranib",,,www.icoa.fr/pkidb/static/img/mol/Cediranib.svg
Cenisertib,nan,1,EMD Serono,NaN,NaN,nan,0,451.2,2.5,99.4,7,3,6,nan,"AURKA
AURKB
AURKC",Other,"Smiles=Cc1cc(ccc1N2CCN(CC2)C)Nc3ncc(c(n3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)F
InChiKey=KSOVGRCOLZZTPF-QMKUDKLTSA-N",nan,nan,Racemic Mixture,"R-763
AS-703569",,,www.icoa.fr/pkidb/static/img/mol/Cenisertib.svg
Ceralasertib,nan,2,Astrazeneca,NaN,NaN,nan,0,412.2,2.9,107.8,7,2,4,"Ceralasertib, also known as AZD6738, is an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis.",nan,,"Smiles=CC1COCCN1c2cc(nc(n2)c3cncc4c3cc[nH]4)C5(CC5)S(=N)(=O)C
InChiKey=DTTJKLNXNZAVSM-UHFFFAOYSA-N",nan,nan,nan,AZD6738,,,www.icoa.fr/pkidb/static/img/mol/Ceralasertib.svg
Cerdulatinib,nan,2.5,Portola pharmaceuticals,NaN,NaN,nan,0,445.2,1.4,133.6,8,3,8,nan,"JAK1
SYK",Tyr,"Smiles=CCS(=O)(=O)N1CCN(CC1)c2ccc(cc2)Nc3ncc(c(n3)NC4CC4)C(=O)N
InChiKey=BGLPECHZZQDNCD-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,PRT-062070,,,www.icoa.fr/pkidb/static/img/mol/Cerdulatinib.svg
Ceritinib,Zykadia,4,Novartis,'4MK',4mkc,1,2,557.2,6.4,105.2,8,3,9,Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.,ALK,Tyr,"Smiles=Cc1cc(c(cc1C2CCNCC2)OC(C)C)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)C(C)C)Cl
InChiKey=VERWOWGGCGHDQE-UHFFFAOYSA-N",2014,US-7153964-B2,Achiral Molecule,"Zykadia
Ceritinib
NVP-LDK378-NX",Y,,www.icoa.fr/pkidb/static/img/mol/Ceritinib.svg
Cobimetinib,Cotellic,4,Hoffmann-La Roche,'EUI',4an2 4lmn,3,1,531.1,3.8,64.6,4,3,4,"For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.",MAP2K1,STE,"Smiles=c1c(cc(c(c1)Nc2c(c(ccc2C(=O)N3C[C@@](C3)(O)[C@H]4NCCCC4)F)F)F)I
InChiKey=BSMCAPRUBJMWDF-KRWDZBQOSA-N",2015,US-7803839-B2,Single Stereoisomer,"Cotellic
RG-7421
GDC-0973
RG-7420
XL-518
Cobimetinib",Y,,www.icoa.fr/pkidb/static/img/mol/Cobimetinib.svg
Copanlisib,Aliqopa,4,Bayer,'6E2',5g2n,1,1,480.2,0.7,139.8,11,2,7,Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.,"PIK3CA
PIK3CB",Atypical,"Smiles=COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5
InChiKey=PZBCKZWLPGJMAO-UHFFFAOYSA-N",2017,US-7511041-B2,Achiral Molecule,"Copanlisib
BAY 80-6946
BAY-80-6946",Y,,www.icoa.fr/pkidb/static/img/mol/Copanlisib.svg
Crenolanib,nan,3,Arog Pharmaceuticals,'6T2',5lby 6bqp,1,0,443.2,3.9,78.4,7,1,5,nan,"FLT3
PDGFRA
PDGFRB",Tyr,"Smiles=CC1(COC1)COc2ccc3c(c2)ncn3c4ccc5cccc(c5n4)N6CCC(CC6)N
InChiKey=DYNHJHQFHQTFTP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CP-868596
ARO-002
Crenolanib",,,www.icoa.fr/pkidb/static/img/mol/Crenolanib.svg
Crizotinib,Xalkori,4,Pfizer,'VGH',2wgj 2xp2 2yfx 3zbf 4anq 4ans 4c9w 5aaa 5aab 5aac 6imz,1,1,449.1,5,78,6,2,5,Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.,"ALK
MET",Tyr,"Smiles=C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4
InChiKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N",2011,US-7230098-B2,Single Stereoisomer,"Xalkori
Crizotinib
PF-2341066",Y,,www.icoa.fr/pkidb/static/img/mol/Crizotinib.svg
Dabrafenib,Tafinlar,4,GlaxoSmithKline,'P06',4xv2 5csw 5hie,1.5,2,519.1,5.4,110.9,7,2,5,Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.,"BRAF
RAF1
SIK1
NEK11
LIMK1","NEK
TKL
CAMK","Smiles=CC(C)(C)c1nc(c(s1)c2ccnc(n2)N)c3cccc(c3F)NS(=O)(=O)c4c(cccc4F)F
InChiKey=BFSMGDJOXZAERB-UHFFFAOYSA-N",2013,US-7994185-B2,Achiral Molecule,"Tafinlar
GSK2118436A
Dabrafenib",Y,,www.icoa.fr/pkidb/static/img/mol/Dabrafenib.svg
Dacomitinib,Vizimpro,4,Pfizer,'1C9',4i23 4i24,1,1,469.2,5.2,79.4,6,2,7,"On october 27, 2018, the FDA approved dacomitinib to treat metastatic non-small-cell lung cancer",EGFR,Tyr,"Smiles=COc1cc2c(cc1NC(=O)/C=C/CN3CCCCC3)c(ncn2)Nc4ccc(c(c4)Cl)F
InChiKey=LVXJQMNHJWSHET-AATRIKPKSA-N",2018,nan,Achiral Molecule,"Dacomitinib
PF-00299804",Y,184-187,www.icoa.fr/pkidb/static/img/mol/Dacomitinib.svg
Dactolisib,nan,2,Novartis,NaN,NaN,nan,1,469.2,5.9,76.5,6,0,3,nan,"PIK3CA
PIK3CB
PIK3CG
PIK3CD
MTOR",Atypical,"Smiles=CC(C)(C#N)c1ccc(cc1)n2c3c4cc(ccc4ncc3n(c2=O)C)c5cc6ccccc6nc5
InChiKey=JOGKUKXHTYWRGZ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Dactolisib
NVP-BEZ235-NX
BEZ-235
NVP-BEZ235",,,www.icoa.fr/pkidb/static/img/mol/Dactolisib.svg
Danusertib,nan,2,Nerviano Medical Sciences,'627',2j50 2v7a 4qo9 5i9z,1,0,474.2,2.6,93.8,6,2,6,nan,"AURKA
AURKB
AURKC",Other,"Smiles=CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3c4c([nH]n3)CN(C4)C(=O)[C@@H](c5ccccc5)OC
InChiKey=XKFTZKGMDDZMJI-HSZRJFAPSA-N",nan,nan,Single Stereoisomer,"Danusertib
PHA-739358",,,www.icoa.fr/pkidb/static/img/mol/Danusertib.svg
Dasatinib,Sprycel,4,Bristol Myers Squibb,'1N1',2gqg 2y6o 2zva 3g5d 3k54 3lfa 3oct 3oht 3qlg 3sxr 4qms 4xey 4xli 5bvw 5h2u 5i9y 5owr 5vcv 6bsd 6fnm,1,0,487.2,3.3,106.5,9,3,7,"For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.","ABL1
SRC
EPHA2
LCK
YES1
KIT
PDGFRB
ABL2
FYN",Tyr,"Smiles=Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl
InChiKey=ZBNZXTGUTAYRHI-UHFFFAOYSA-N",2006,US-6596746-B1,Achiral Molecule,"Sprycel;Dasatinib
BMS-354825-03
BMS-354825
Dasatinib",Y,280-286,www.icoa.fr/pkidb/static/img/mol/Dasatinib.svg
Decernotinib,nan,2,Vertex Pharmaceuticals,'VJK',4yti,1,0,392.2,3.3,95.6,5,3,6,nan,JAK3,Tyr,"Smiles=CC[C@](C)(C(=O)NCC(F)(F)F)Nc1ccnc(n1)c2c[nH]c3c2cccn3
InChiKey=ASUGUQWIHMTFJL-QGZVFWFLSA-N",nan,nan,Single Stereoisomer,"VRT-831509
Adelatinib
VX-509
Decernotinib",,,www.icoa.fr/pkidb/static/img/mol/Decernotinib.svg
Defactinib,nan,2,Verastem,'7KD',5mah,1,1,510.1,2.4,142.1,9,3,8,nan,"PTK2
PTK2B",Tyr,"Smiles=CNC(=O)c1ccc(cc1)Nc2ncc(c(n2)NCc3c(nccn3)N(C)S(=O)(=O)C)C(F)(F)F
InChiKey=FWLMVFUGMHIOAA-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"PF-04554878
VS-6063
Defactinib",,,www.icoa.fr/pkidb/static/img/mol/Defactinib.svg
Derazantinib,nan,1.5,ArQule,NaN,NaN,nan,1,468.2,5.5,59.1,5,2,9,"Derazantinib (ARQ087) is an orally bioavailable, non-selective FGFR inhibitor being investigated for antineoplastic activity.",nan,,"Smiles=COCCNCCc1cccc(c1)Nc2ncc3c(n2)-c4ccccc4[C@@H](C3)c5ccccc5F
InChiKey=KPJDVVCDVBFRMU-AREMUKBSSA-N",nan,nan,nan,,,,www.icoa.fr/pkidb/static/img/mol/Derazantinib.svg
Dezapelisib,nan,0,Incyte Corporation,NaN,NaN,nan,0,421.1,3.7,100.9,8,2,4,nan,nan,,"Smiles=Cc1csc2n1c(=O)c(c(n2)[C@H](C)Nc3c4c([nH]cn4)ncn3)c5cccc(c5)F
InChiKey=RSIWALKZYXPAGW-NSHDSACASA-N",nan,nan,Single Stereoisomer,"INCB040093
Dezapelisib",,,www.icoa.fr/pkidb/static/img/mol/Dezapelisib.svg
Dilmapimod,nan,2,GlaxoSmithKline,NaN,NaN,nan,0,456.1,2.9,100.3,7,3,6,"Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others.","MAPK14
MAPK11
MAPK13
MAPK12",CMGC,"Smiles=Cc1cc(ccc1c2c3ccc(=O)n(c3nc(n2)NC(CO)CO)c4c(cccc4F)F)F
InChiKey=ORVNHOYNEHYKJG-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Dilmapimod
GW681323
SB-681323",,,www.icoa.fr/pkidb/static/img/mol/Dilmapimod.svg
Dinaciclib,nan,3,Schering-Plough,NaN,NaN,nan,0,396.2,2.3,92.6,7,2,7,nan,"CDK4
CDK6
BRDT","(*)
CMGC","Smiles=CCc1cnn2c1nc(cc2NCc3ccc[n+](c3)[O-])N4CCCC[C@H]4CCO
InChiKey=PIMQWRZWLQKKBJ-SFHVURJKSA-N",nan,nan,Single Stereoisomer,"MK-7965
SCH-727965
Dinaciclib",,,www.icoa.fr/pkidb/static/img/mol/Dinaciclib.svg
Doramapimod,nan,2,Boehringer Ingelheim,'B96',1kv2 3fzs 3npc 4jvg 4twn 5n66 6gtt,2,2,527.3,6,80.7,6,2,7,nan,MAPK14,CMGC,"Smiles=Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)Nc3ccc(c4c3cccc4)OCCN5CCOCC5
InChiKey=MVCOAUNKQVWQHZ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Doramapimod
BIRB-796",,,www.icoa.fr/pkidb/static/img/mol/Doramapimod.svg
Dovitinib,nan,3,Novartis,'38O',4tyi 5a46 5am6 5am7 5owq,1,0,392.2,2.5,94,5,3,2,nan,"FGFR3
VEGFA
FGFR1
PDGFRA
KIT
CSF1R","(*)
Tyr","Smiles=CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N
InChiKey=PIQCTGMSNWUMAF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GFKI-258
TKI-258
CHIR-258
NVP-TKI258
Dovitinib",,,www.icoa.fr/pkidb/static/img/mol/Dovitinib.svg
Duvelisib,Copiktra,4,Infinity Pharmacueticals,NaN,NaN,nan,0,416.1,4.5,88.5,6,2,4,"On october 27, 2018, the FDA approved duvelisib to treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma","PIK3CD
PIK3CG",Atypical,"Smiles=C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4
InChiKey=SJVQHLPISAIATJ-ZDUSSCGKSA-N",2018,nan,Single Stereoisomer,"INK-1197
INK-1147
IPI-145
Duvelisib",Y,>190,www.icoa.fr/pkidb/static/img/mol/Duvelisib.svg
Encorafenib,Braftovi,4,Novartis,NaN,NaN,nan,1,539.2,3.9,140.1,9,3,9,"On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",BRAF,TKL,"Smiles=C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
InChiKey=CMJCXYNUCSMDBY-ZDUSSCGKSA-N",2018,nan,Single Stereoisomer,"NVP-LGX818-NXA
LGX-818
Encorafenib
NVP-LGX818",Y,,www.icoa.fr/pkidb/static/img/mol/Encorafenib.svg
Ensartinib,nan,3,Xcovery,NaN,NaN,nan,1,560.2,4.7,122.5,7,3,6,nan,ALK,Tyr,"Smiles=C[C@@H]1CN(C[C@@H](N1)C)C(=O)c2ccc(cc2)NC(=O)c3cc(c(nn3)N)O[C@H](C)c4c(ccc(c4Cl)F)Cl
InChiKey=GLYMPHUVMRFTFV-QLFBSQMISA-N",nan,nan,nan,"X-396
X396
X-396 CAPSULES
ENSARTINIB",,,www.icoa.fr/pkidb/static/img/mol/Ensartinib.svg
Entospletinib,nan,2,Gilead Sciences,'CG9',4puz,1,0,411.2,3.9,83.4,7,2,4,nan,SYK,Tyr,"Smiles=c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6
InChiKey=XSMSNFMDVXXHGJ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GS-9973
Entospletinib",,,www.icoa.fr/pkidb/static/img/mol/Entospletinib.svg
Entrectinib,Rozlytrek,4,Ignyta,'YMX',5fto 5kvt,1,2,560.3,5,85.5,6,3,7,"On august 2019, FDA approved entrectinib to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and to treat adult and pediatric patients 12 years of age and older with solid tumors","NTRK1
NTRK2
NTRK3
ROS1
ALK",Tyr,"Smiles=CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4c5cc(ccc5[nH]n4)Cc6cc(cc(c6)F)F
InChiKey=HAYYBYPASCDWEQ-UHFFFAOYSA-N",2019,nan,Achiral Molecule,"Entrectinib
RXDX-101
NMS-E628",Y,,www.icoa.fr/pkidb/static/img/mol/Entrectinib.svg
Enzastaurin,nan,3,Eli Lilly,NaN,NaN,nan,1,515.2,4.9,72.2,6,1,5,nan,nan,,"Smiles=Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7
InChiKey=AXRCEOKUDYDWLF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"LY-317615
Enzastaurin",,,www.icoa.fr/pkidb/static/img/mol/Enzastaurin.svg
Erdafitinib,Balversa,4,Janssen,'5SF',5ew8,1,0,446.2,4.2,77.3,8,1,9,"On april 2019, FDA approved erdafitinib to treat adult patients with locally advanced or metastatic bladder cancer",FGFR1,Tyr,"Smiles=CC(C)NCCN(c1ccc2c(c1)nc(cn2)c3cnn(c3)C)c4cc(cc(c4)OC)OC
InChiKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N",2019,nan,Achiral Molecule,"Erdafitinib
JNJ-42756493",Y,,www.icoa.fr/pkidb/static/img/mol/Erdafitinib.svg
Erlotinib,Tarceva,4,Osi Pharmaceuticals,'AQ4',1m17 4hjo 6dwn,1.5,0,393.2,3.4,74.7,7,1,10,"For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.","EGFR
NR1I2","(*)
Tyr","Smiles=COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C
InChiKey=AAKJLRGGTJKAMG-UHFFFAOYSA-N",2004,US-5747498-A,Achiral Molecule,"Tarceva
Erlotinib
OSI-774
RG-1415
CP-358774
R-1415
Ro-508231",Y,,www.icoa.fr/pkidb/static/img/mol/Erlotinib.svg
Evobrutinib,nan,2,Merck,'MZJ',6omu,nan,0,429.2,4.4,93.4,6,2,7,nan,BTK,Tyr,"Smiles=C=CC(=O)N1CCC(CC1)CNc2c(c(ncn2)N)c3ccc(cc3)Oc4ccccc4
InChiKey=QUIWHXQETADMGN-UHFFFAOYSA-N",nan,nan,nan,EVOBRUTINIB,,,www.icoa.fr/pkidb/static/img/mol/Evobrutinib.svg
Famitinib,nan,3,Jiangsu Hengrui Medicine,NaN,NaN,nan,0,410.2,3.3,68.4,3,2,6,nan,"KIT
KDR
FLT4
PDGFRA
PDGFRB
FLT1
FLT3",Tyr,"Smiles=CCN(CC)CCN1CCc2c(c(c([nH]2)/C=C\3/c4cc(ccc4NC3=O)F)C)C1=O
InChiKey=GKEYKDOLBLYGRB-LGMDPLHJSA-N",nan,nan,nan,SHR-1020,,,www.icoa.fr/pkidb/static/img/mol/Famitinib.svg
Fasudil,nan,4,Asahi Kasei Pharma Corp,'M77',1q8w 2esm 2f2u 2gni 3tku 5lcp 5nw8 5o0e 5ok3 5vef 6em2 6emb 6ers 6erw 6i2a 6i2c,nan,0,291.1,1.2,62.3,4,1,2,Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2.,nan,,"Smiles=c1cc2cnccc2c(c1)S(=O)(=O)N3CCCNCC3
InChiKey=NGOGFTYYXHNFQH-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"HA-1077
Fasudil
ZK-258594
AT-877",N,,www.icoa.fr/pkidb/static/img/mol/Fasudil.svg
Fedratinib,Inrebic,4,Sanofi,'2TA',4ogj 4ps5,nan,1,524.3,4.8,108.5,8,3,10,"On august 2019, FDA approved fedratinib to treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis","JAK2
FLT3
BRD4","(*)
Tyr","Smiles=Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4
InChiKey=JOOXLOJCABQBSG-UHFFFAOYSA-N",2019,nan,Achiral Molecule,"SAR-302503
Fedratinib
TG101348
TG-101348",Y,,www.icoa.fr/pkidb/static/img/mol/Fedratinib.svg
Filgotinib,nan,3,Galapagos,'2HB',4p7e 5ut5,1,0,425.2,2,96.7,7,1,5,nan,JAK1,Tyr,"Smiles=c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5
InChiKey=RIJLVEAXPNLDTC-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"G-146034
GLPG-0634
Filgotinib",,,www.icoa.fr/pkidb/static/img/mol/Filgotinib.svg
Flumatinib,nan,3,Jiangsu Hengrui Medicine,NaN,NaN,nan,2,562.2,5,99.2,8,2,7,nan,"BCR
ABL1
PDGFRB
KIT","Atypical
Tyr","Smiles=Cc1c(cc(cn1)NC(=O)c2ccc(c(c2)C(F)(F)F)CN3CCN(CC3)C)Nc4nccc(n4)c5cccnc5
InChiKey=BJCJYEYYYGBROF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"HHGV-678
Flumatinib",,,www.icoa.fr/pkidb/static/img/mol/Flumatinib.svg
Foretinib,nan,2,GlaxoSmithKline,'88Z',3lq8 5ia4 6i2y 6sd9 6sdc,2,2,632.2,5.8,111.2,8,2,12,nan,"MET
KDR",Tyr,"Smiles=COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
InChiKey=CXQHYVUVSFXTMY-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"EXEL-2880
Foretinib
GSK1363089G
GSK1363089
GSK-1363089
XL-880
GSK089",,,www.icoa.fr/pkidb/static/img/mol/Foretinib.svg
Fostamatinib,Tavalisse,4,Rigel Pharmaceuticals,'2RC',4o75,nan,2,580.1,3.1,186.7,12,4,10,Indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment,SYK,Tyr,"Smiles=CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C
InChiKey=GKDRMWXFWHEQQT-UHFFFAOYSA-N",2018,nan,Achiral Molecule,"R-935788
R-788 Free acid
R-935788 Free acid
Fostamatinib
R-788",Y,,www.icoa.fr/pkidb/static/img/mol/Fostamatinib.svg
Fruquintinib,nan,3,Hutchison MediPharma,NaN,NaN,nan,0,393.1,3.9,95.7,7,1,5,nan,"FLT1
KDR
FLT4",Tyr,"Smiles=Cc1c(c2ccc(cc2o1)Oc3c4cc(c(cc4ncn3)OC)OC)C(=O)NC
InChiKey=BALLNEJQLSTPIO-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,"HMP-013

HMPL-013",,,www.icoa.fr/pkidb/static/img/mol/Fruquintinib.svg
Galunisertib,nan,2,Eli Lilly,NaN,NaN,nan,0,369.2,3.5,86.7,5,1,3,nan,TGFBR1,TKL,"Smiles=Cc1cccc(n1)c2c(c3n(n2)CCC3)c4ccnc5c4cc(cc5)C(=O)N
InChiKey=IVRXNBXKWIJUQB-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Galunisertib
LY-2157299",,,www.icoa.fr/pkidb/static/img/mol/Galunisertib.svg
Gandotinib,nan,2,Eli Lilly,NaN,NaN,nan,0,469.2,4,83.4,7,2,6,nan,JAK2,Tyr,"Smiles=Cc1cc(n[nH]1)Nc2cc(c3nc(c(n3n2)Cc4ccc(cc4F)Cl)C)CN5CCOCC5
InChiKey=SQSZANZGUXWJEA-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"LY-2784544
Gandotinib",,,www.icoa.fr/pkidb/static/img/mol/Gandotinib.svg
Gedatolisib,nan,2,Pfizer,NaN,NaN,nan,1,615.3,3,128.3,10,2,7,nan,"PIK3CA
PIK3CB
PIK3CG
PIK3CD
MTOR",Atypical,"Smiles=CN(C)C1CCN(CC1)C(=O)c2ccc(cc2)NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6
InChiKey=DWZAEMINVBZMHQ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"PKI-587
Gedatolisib
PF-05212384",,,www.icoa.fr/pkidb/static/img/mol/Gedatolisib.svg
Gefitinib,Iressa,4,Astrazeneca,'IRE',2ito 2ity 2itz 3ug2 4i22 4wkq 5y7z 5y80,1.5,0,446.2,4.3,68.7,7,1,8,For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.,EGFR,Tyr,"Smiles=COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F
InChiKey=XGALLCVXEZPNRQ-UHFFFAOYSA-N",2003,US-5770599-A,Achiral Molecule,"Iressa
Gefitinib
Iressa
ZD-1839",Y,,www.icoa.fr/pkidb/static/img/mol/Gefitinib.svg
Gilteritinib,Xospata,4,Astellas Pharma,'C6F',6jqr,nan,1,552.4,2.7,121.1,10,3,9,"On november 28, 2018, the FDA approved gilteritinib to treat patients who have relapsed or refractory acute myeloid leukemia (AML)","FLT3
AXL
ALK",Tyr,"Smiles=CCc1c(nc(c(n1)C(=O)N)Nc2ccc(c(c2)OC)N3CCC(CC3)N4CCN(CC4)C)NC5CCOCC5
InChiKey=GYQYAJJFPNQOOW-UHFFFAOYSA-N",2018,nan,Achiral Molecule,"ASP-2215
Gilteritinib",Y,,www.icoa.fr/pkidb/static/img/mol/Gilteritinib.svg
Glesatinib,nan,2,Mirati Therapeutics,NaN,NaN,nan,2,619.2,6.2,97.4,8,3,11,nan,"MET
TEK
FLT1
KDR
FLT4
MST1R",Tyr,"Smiles=COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F
InChiKey=YRCHYHRCBXNYNU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MG90265H9
MG90265gly
MGCD265
MG90265
MG90265X
Glesatinib",,,www.icoa.fr/pkidb/static/img/mol/Glesatinib.svg
Golvatinib,nan,2,Eisai,'GV0',5ia5,2,1,633.3,4.8,119.1,7,3,8,nan,"MET
KDR",Tyr,"Smiles=CN1CCN(CC1)C2CCN(CC2)C(=O)Nc3cc(ccn3)Oc4ccc(c(c4)F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
InChiKey=UQRCJCNVNUFYDX-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"E-7050
Golvatinib
E7050",,,www.icoa.fr/pkidb/static/img/mol/Golvatinib.svg
Henatinib,nan,1,Jiangsu Hengrui Medicine,NaN,NaN,nan,0,468.2,2,97.9,5,3,5,nan,KDR,Tyr,"Smiles=Cc1c([nH]c2c1C(=O)N(CCC2)C[C@@H](CN3CCOCC3)O)/C=C\4/c5cc(ccc5NC4=O)F
InChiKey=MCTXSDCWFQAGFS-UEXNTNOUSA-N",nan,nan,Single Stereoisomer,,,,www.icoa.fr/pkidb/static/img/mol/Henatinib.svg
Ibrutinib,Imbruvica,4,Pharmacyclics,'1E8',4ifg 4rz7 5p9i 5yu9,1.5,0,440.2,4.2,99.2,7,1,5,"Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia",BTK,Tyr,"Smiles=C=CC(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N
InChiKey=XYFPWWZEPKGCCK-GOSISDBHSA-N",2013,US-7514444-B2,Single Stereoisomer,"Imbruvica
PCI-32765
PCI-32765-00
Ibrutinib
CRA-032765",Y,149-158,www.icoa.fr/pkidb/static/img/mol/Ibrutinib.svg
Icotinib,nan,4,Zhejiang Beta Pharma,NaN,NaN,nan,0,391.2,3.2,74.7,7,1,2,"Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.",EGFR,Tyr,"Smiles=C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4
InChiKey=QQLKULDARVNMAL-UHFFFAOYSA-N",2011,nan,nan,BPI-2009H,N,,www.icoa.fr/pkidb/static/img/mol/Icotinib.svg
Idelalisib,Zydelig,4,Gilead Sciences,'40L',4xe0,1,0,415.2,3.8,101.4,7,2,5,"Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.",PIK3CD,Atypical,"Smiles=CC[C@@H](c1nc2cccc(c2c(=O)n1c3ccccc3)F)Nc4c5c([nH]cn5)ncn4
InChiKey=IFSDAJWBUCMOAH-HNNXBMFYSA-N",2014,US-6800620-B2,Single Stereoisomer,"Zydelig
GS-1101
GS-11CAL-101
Idelalisib
CAL-101",Y,,www.icoa.fr/pkidb/static/img/mol/Idelalisib.svg
Ilorasertib,nan,2,Abbott Laboratories,NaN,NaN,nan,1,488.1,5.2,118.1,7,4,6,nan,"AURKA
AURKB
AURKC
FLT1
PDGFRA
PDGFRB","Tyr
Other","Smiles=c1cc(cc(c1)F)NC(=O)Nc2ccc(cc2)c3csc4c3c(ncc4c5cnn(c5)CCO)N
InChiKey=WPHKIQPVPYJNAX-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"A-968660
ABT-348
Ilorasertib",,,www.icoa.fr/pkidb/static/img/mol/Ilorasertib.svg
Imatinib,Gleevec,4,Novartis,'STI',1iep 1opj 1t46 1xbb 2hyy 2oiq 2pl0 3fw1 3gvu 3hec 3k5v 3ms9 3mss 3oez 3pyy 4bkj 4csv 4r7i 5mqt 6hd4 6hd6 6npe 6npu 6npv,2,0,493.3,4.6,86.3,7,2,7,"For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).","KIT
RET
NTRK1
CSF1R
PDGFRA
DDR1
ABL1
PDGFRB",Tyr,"Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C
InChiKey=KTUFNOKKBVMGRW-UHFFFAOYSA-N",2001,US-6894051-B1,Achiral Molecule,"Gleevec
Imatinib
STI-571",Y,226,www.icoa.fr/pkidb/static/img/mol/Imatinib.svg
Infigratinib,nan,2,Novartis,'07J',3tt0,1,2,559.2,5.4,95.1,8,2,8,nan,"FGFR1
FGFR2
FGFR3",Tyr,"Smiles=CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl
InChiKey=QADPYRIHXKWUSV-UHFFFAOYSA-N",nan,nan,nan,"BGJ-398
NVP-BGJ398",,,www.icoa.fr/pkidb/static/img/mol/Infigratinib.svg
Ipatasertib,nan,3,Hoffmann-La Roche,'0RF',4ekl,1,0,457.2,3.1,81.6,6,2,6,nan,"AKT1
AKT2
AKT3",AGC,"Smiles=C[C@@H]1C[C@H](c2c1c(ncn2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)c4ccc(cc4)Cl)O
InChiKey=GRZXWCHAXNAUHY-NSISKUIASA-N",nan,nan,Single Stereoisomer,"GDC-0068
Ipatasertib
RG-7440",,,www.icoa.fr/pkidb/static/img/mol/Ipatasertib.svg
Itacitinib,nan,3,Incyte Corporation,NaN,NaN,nan,1,553.2,3.6,119.6,8,1,5,nan,JAK1,Tyr,"Smiles=c1cnc-2[nH]cnc(c12)c3cnn(c3)C4(CN(C4)C5CCN(CC5)C(=O)c6ccnc(c6F)C(F)(F)F)CC#N
InChiKey=KTBSXLIQKWEBRB-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"INCB-039110
INCB-39110
Itacitinib
INCB039110",,,www.icoa.fr/pkidb/static/img/mol/Itacitinib.svg
Lapatinib,Tykerb,4,GlaxoSmithKline,'FMM',1xkk 3bbt,1.5,2,580.1,6.1,106.4,8,2,11,"Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.","EGFR
ERBB2",Tyr,"Smiles=CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F
InChiKey=BCFGMOOMADDAQU-UHFFFAOYSA-N",2007,US-6391874-B1,Achiral Molecule,"Tyverb
GW-2016
GW-572016
Lapatinib",Y,,www.icoa.fr/pkidb/static/img/mol/Lapatinib.svg
Larotrectinib,Vitrakvi,4,Array BioPharma,NaN,NaN,nan,0,428.2,2.9,86,6,2,3,"On november 26, 2018, the FDA approved larotrectinib to treat patients whose cancers have a specific genetic feature (biomarker)","NTRK1
NTRK2
NTRK3",Tyr,"Smiles=c1cc(c(cc1F)[C@H]2CCCN2c3ccn4c(n3)c(cn4)NC(=O)N5CC[C@@H](C5)O)F
InChiKey=NYNZQNWKBKUAII-KBXCAEBGSA-N",2018,nan,Single Stereoisomer,"Larotrectinib
LOXO-101",Y,,www.icoa.fr/pkidb/static/img/mol/Larotrectinib.svg
Lazertinib,nan,1,Genosco,NaN,NaN,nan,1,554.3,4.1,109.7,10,2,10,"Lazertinib (YH-25448, GNS-1480) is an inhibitor of the aberrant activity of EGFR mutant kinases, that was originally developed by Yuhan Corporation for antineoplastic potential in cancers with (acquired) resistance to existing EGFR tyrosine kinase inhibitors, in particular for EGFR mutation positive, advanced non-small cell lung cancer (NSCLC). In addition to predicted efficacy for the treatment of primary lung and extracranial lesions, lazertinib is expected to be beneficial for NSCLC brain metastases as it is able to cross the blood brain barrier.",nan,,"Smiles=CN(C)Cc1cn(nc1c2ccccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N5CCOCC5)NC(=O)C=C
InChiKey=RRMJMHOQSALEJJ-UHFFFAOYSA-N",nan,nan,nan,,,,www.icoa.fr/pkidb/static/img/mol/Lazertinib.svg
Leniolisib,nan,0,Novartis,'9NQ',5o83,nan,0,450.2,2.9,83.5,7,1,5,nan,nan,,"Smiles=CCC(=O)N1CC[C@@H](C1)Nc2c3c(ncn2)CCN(C3)c4cc(c(nc4)OC)C(F)(F)F
InChiKey=MWKYMZXCGYXLPL-ZDUSSCGKSA-N",nan,nan,Single Stereoisomer,"CDZ173-NX
Leniolisib",,,www.icoa.fr/pkidb/static/img/mol/Leniolisib.svg
Lenvatinib,Kisplyx;Lenvima,4,Eisai,'LEV',3wzd 5zv2,1.5,0,426.1,4.1,115.6,5,3,6,"Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.","FLT1
KDR
FLT4
FGFR1
FGFR2
FGFR3
FGFR4
KIT",Tyr,"Smiles=COc1cc2c(cc1C(=O)N)c(ccn2)Oc3ccc(c(c3)Cl)NC(=O)NC4CC4
InChiKey=WOSKHXYHFSIKNG-UHFFFAOYSA-N",2015,US-7253286-B2,Achiral Molecule,"Lenvima;Kisplyx
ER-203492-00
Lenvatinib",Y,,www.icoa.fr/pkidb/static/img/mol/Lenvatinib.svg
Lestaurtinib,nan,3,Cephalon,NaN,NaN,nan,0,439.2,3.5,88.7,6,3,1,nan,FLT3,Tyr,"Smiles=C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O
InChiKey=UIARLYUEJFELEN-LROUJFHJSA-N",nan,nan,Single Stereoisomer,"KT-5555
KT-555
Lestaurtinib
SPM-924
SP-924
A-154475
CEP-701
Cep-701
SP924
A-1544750",,,www.icoa.fr/pkidb/static/img/mol/Lestaurtinib.svg
Linifanib,nan,3,Abbott Laboratories,NaN,NaN,nan,0,375.1,4.9,95.8,3,4,3,nan,"FLT3
CSF1R
KDR",Tyr,"Smiles=Cc1ccc(c(c1)NC(=O)Nc2ccc(cc2)c3cccc4c3c(n[nH]4)N)F
InChiKey=MPVGZUGXCQEXTM-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"ABT-869
RG-3635
Linifanib
AL-39324",,,www.icoa.fr/pkidb/static/img/mol/Linifanib.svg
Linsitinib,nan,3,Osi Pharmaceuticals,NaN,NaN,nan,0,421.2,4.8,89.3,6,2,3,nan,IGF1R,Tyr,"Smiles=C[C@]1(C[C@@H](C1)c2n3c(c(ncc3)N)c(n2)c4cc5nc(ccc5cc4)c6ccccc6)O
InChiKey=PKCDDUHJAFVJJB-VLZXCDOPSA-N",nan,nan,Single Stereoisomer,"Linsitinib
ASP-7487
OSI-906
OSI-906AA",,,www.icoa.fr/pkidb/static/img/mol/Linsitinib.svg
Lorlatinib,Lorbrena,4,Pfizer,'5P8',4cli 4clj 4uxl 5a9u 5aa8 5aa9,1,0,406.2,2.8,110.1,7,1,0,"On november 2, 2018, the FDA approved lorlatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer","ALK
ROS1",Tyr,"Smiles=C[C@@H]1c2cc(ccc2C(=O)N(Cc3c(c(n(n3)C)C#N)-c4cc(c(nc4)N)O1)C)F
InChiKey=IIXWYSCJSQVBQM-LLVKDONJSA-N",2018,nan,Single Stereoisomer,"Lorlatinib
PF-06463922",Y,,www.icoa.fr/pkidb/static/img/mol/Lorlatinib.svg
Losmapimod,nan,3,GlaxoSmithKline,NaN,NaN,nan,0,383.2,3.9,71.1,3,2,5,nan,"MAPK14
MAPK11
MAPK13
MAPK12",CMGC,"Smiles=Cc1c(cc(cc1F)C(=O)NC2CC2)c3ccc(cn3)C(=O)NCC(C)(C)C
InChiKey=KKYABQBFGDZVNQ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GSKAHAB
GW856553
GW856553X
Losmapimod",,,www.icoa.fr/pkidb/static/img/mol/Losmapimod.svg
Lucitanib,nan,2,Clovis Oncology,'3ZC',4rwl,1,0,443.2,4.4,95.7,6,2,7,nan,"FLT1
KDR
FLT4
FGFR1
FGFR2",Tyr,"Smiles=CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC
InChiKey=CUDVHEFYRIWYQD-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"E-3810
CO-3810
Lucitanib
S-80881
AL-3810",,,www.icoa.fr/pkidb/static/img/mol/Lucitanib.svg
Masitinib,Kinavet;Masivet,3,AB Science,'G65',5mql,nan,1,498.2,5.3,73.4,7,2,7,nan,"KIT
PDGFRA
PDGFRB
FGFR1
FGFR2
FGFR3",Tyr,"Smiles=Cc1ccc(cc1Nc2nc(cs2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C
InChiKey=WJEOLQLKVOPQFV-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Masivet;Kinavet
Masitinib
AB-1010",,,www.icoa.fr/pkidb/static/img/mol/Masitinib.svg
Mavelertinib,nan,0,Pfizer,NaN,NaN,nan,0,415.2,0.7,115,10,2,6,nan,nan,,"Smiles=Cn1cc(c(n1)OC)Nc2c3c(nc(n2)N4C[C@H]([C@@H](C4)F)NC(=O)C=C)n(cn3)C
InChiKey=JYIUNVOCEFIUIU-GHMZBOCLSA-N",nan,nan,Single Stereoisomer,"PF-06747775
Mavelertinib",,,www.icoa.fr/pkidb/static/img/mol/Mavelertinib.svg
Merestinib,nan,2,Eli Lilly,'L1X',4eev,2,2,552.2,5.7,106.8,7,2,6,nan,MET,Tyr,"Smiles=Cc1ccc(c(=O)n1c2ccc(cc2)F)C(=O)Nc3ccc(c(c3)F)Oc4cc5cnn(c5cc4c6c[nH]nc6)C
InChiKey=QHADVLVFMKEIIP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Merestinib
LY-2801653",,,www.icoa.fr/pkidb/static/img/mol/Merestinib.svg
Midostaurin,Rydapt,4,Novartis Pharmaceuticals Corp,'2K2',4nct,nan,2,570.2,5.9,77.7,6,1,3,"On april 28 , 2017, the FDA approved midostaurin to treat acute myeloid leukemia",nan,,"Smiles=C[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)N(C)C(=O)c9ccccc9)OC
InChiKey=BMGQWWVMWDBQGC-IIFHNQTCSA-N",2017,US-7973031-B2,Single Stereoisomer,"Rydapt
Midostaurin
NVP-PKC412
PKC-412
CGP-41251",Y,235-260,www.icoa.fr/pkidb/static/img/mol/Midostaurin.svg
Milciclib,nan,2,Nerviano Medical Sciences,'P48',2wih 5vc6 5vd1,1,0,460.3,2.6,91.2,8,2,4,nan,"CDK1
NTRK1","Tyr
CMGC","Smiles=CC1(Cc2cnc(nc2-c3c1c(nn3C)C(=O)NC)Nc4ccc(cc4)N5CCN(CC5)C)C
InChiKey=RXZMYLDMFYNEIM-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"PHA-848125
Milciclib",,,www.icoa.fr/pkidb/static/img/mol/Milciclib.svg
Momelotinib,nan,3,Ym Biosciences Australia,'C87',6fdz,nan,0,414.2,3,103.2,7,2,6,nan,"JAK1
JAK2
JAK3",Tyr,"Smiles=c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N
InChiKey=ZVHNDZWQTBEVRY-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CYT-11387
GS-0387
Momelotinib
CYT-387",,,www.icoa.fr/pkidb/static/img/mol/Momelotinib.svg
Motesanib,nan,3,Amgen,'706',3efl,2,0,373.2,4,78.9,5,3,5,nan,"FLT1
KDR
FLT4
PDGFRA
PDGFRB
KIT
RET",Tyr,"Smiles=CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C
InChiKey=RAHBGWKEPAQNFF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"AMG-706
Motesanib",,,www.icoa.fr/pkidb/static/img/mol/Motesanib.svg
Mubritinib,nan,1,Takeda,NaN,NaN,nan,1,468.2,6.1,66,6,0,10,nan,"EGFR
ERBB2",Tyr,"Smiles=c1cc(ccc1CCCCn2ccnn2)OCc3coc(n3)/C=C/c4ccc(cc4)C(F)(F)F
InChiKey=ZTFBIUXIQYRUNT-MDWZMJQESA-N",nan,nan,Achiral Molecule,"TAK-165
Mubritinib",,,www.icoa.fr/pkidb/static/img/mol/Mubritinib.svg
Naquotinib,nan,3,Astellas Pharma,'8RC',5y9t,nan,1,562.3,2.3,120.2,9,2,9,nan,EGFR,Tyr,"Smiles=CCc1c(nc(c(n1)C(=O)N)Nc2ccc(cc2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C
InChiKey=QKDCLUARMDUUKN-XMMPIXPASA-N",nan,nan,Single Stereoisomer,"Naquotinib
ASP8273",,,www.icoa.fr/pkidb/static/img/mol/Naquotinib.svg
Nazartinib,nan,3,Novartis,NaN,NaN,nan,0,494.2,4.3,83.4,6,1,6,nan,nan,,"Smiles=Cc1cc(ccn1)C(=O)Nc2nc3cccc(c3n2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)Cl
InChiKey=IOMMMLWIABWRKL-WUTDNEBXSA-N",nan,nan,nan,NAZARTINIB,,,www.icoa.fr/pkidb/static/img/mol/Nazartinib.svg
Neflamapimod,nan,2,EIP Pharma,'52P',3fc1 3hp5 3zsi,nan,1,435,5.5,47.3,5,0,3,nan,MAPK14,CMGC,"Smiles=c1cc(c(c(c1)Cl)c2c3ccc(nn3cnc2=O)Sc4ccc(cc4F)F)Cl
InChiKey=VEPKQEUBKLEPRA-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Neflamapimod
VD-31
VRT-031745
VX-745
745",,,www.icoa.fr/pkidb/static/img/mol/Neflamapimod.svg
Nemiralisib,nan,0,GlaxosmithKline,'VVX',5ae8,nan,0,440.2,4.9,77,5,2,5,nan,nan,,"Smiles=CC(C)N1CCN(CC1)Cc2cnc(o2)c3cc(cc4c3cn[nH]4)c5cccc6c5cc[nH]6
InChiKey=MCIDWGZGWVSZMK-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,"GSK2269557A
GSK-2269557
Nemiralisib",,,www.icoa.fr/pkidb/static/img/mol/Nemiralisib.svg
Neratinib,Nerlynx,4,Puma Biotechnology,NaN,NaN,nan,2,556.2,5.9,112.4,8,2,11,"For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy","ERBB2
EGFR",Tyr,"Smiles=CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4
InChiKey=JWNPDZNEKVCWMY-VQHVLOKHSA-N",2017,US-6288082-B1,Achiral Molecule,"WAY-179272
CDP-820
Neratinib
HKI-272",Y,,www.icoa.fr/pkidb/static/img/mol/Neratinib.svg
Netarsudil,Rhopressa,4,Aerie Pharmaceutical,NaN,NaN,nan,0,453.2,4.9,94.3,5,2,7,"On december 18, 2017, the FDA approved netarsudil to treat glaucoma or ocular hypertension",nan,,"Smiles=Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3
InChiKey=OURRXQUGYQRVML-AREMUKBSSA-N",2017,nan,Racemic Mixture,AR-13324,Y,,www.icoa.fr/pkidb/static/img/mol/Netarsudil.svg
Nilotinib,Tasigna,4,Novartis,'NIL',3cs9 3gp0 5mo4,2,2,529.2,6.4,97.6,7,2,6,"For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).","ABL1
KIT",Tyr,"Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F
InChiKey=HHZIURLSWUIHRB-UHFFFAOYSA-N",2007,US-7169791-B2,Achiral Molecule,"Tasigna
Nilotinib
AMN-107",Y,,www.icoa.fr/pkidb/static/img/mol/Nilotinib.svg
Ningetinib,nan,1.5,HEC Pharm,NaN,NaN,nan,2,556.2,5.4,107.6,8,2,8,"Ningetinib, also known as CT-053 or DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration.",nan,,"Smiles=Cc1c(c(=O)n(n1C)c2ccccc2)C(=O)Nc3ccc(c(c3)F)Oc4ccnc5c4ccc(c5)OCC(C)(C)O
InChiKey=VQYYQSZNRVQLIS-UHFFFAOYSA-N",nan,nan,nan,NINGETINIB,,,www.icoa.fr/pkidb/static/img/mol/Ningetinib.svg
Nintedanib,Ofev;Vargatef,4,Boehringer Ingelheim,'XIN',3c7q 5maf 5te0 6nec,1,1,539.3,3.6,94.2,7,2,7,Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).,"FLT1
KDR
FLT4
FGFR1
FGFR2
FGFR3
FLT3
LCK
LYN
SRC",Tyr,"Smiles=CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5
InChiKey=XZXHXSATPCNXJR-ZIADKAODSA-N",2014,US-6762180-B1,Achiral Molecule,"Ofev;Vargatef
Nintedanib
BIBF-1120",Y,,www.icoa.fr/pkidb/static/img/mol/Nintedanib.svg
Oclacitinib,nan,0,Pfizer,NaN,NaN,nan,0,337.2,1.5,91,5,2,5,nan,"JAK1
JAK2
JAK3",Tyr,"Smiles=CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(c2ncnc3c2cc[nH]3)C
InChiKey=HJWLJNBZVZDLAQ-HAQNSBGRSA-N",nan,nan,Single Stereoisomer,"Oclacitinib
JAKI
PF-03394197",,,www.icoa.fr/pkidb/static/img/mol/Oclacitinib.svg
Olmutinib,nan,2,Hanmi Pharmaceutical,NaN,NaN,nan,1,486.2,5.1,82.6,8,2,7,For use in treatment of metastatic T790M mutation positive non-small cell lung cancer,EGFR,Tyr,"Smiles=CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C
InChiKey=FDMQDKQUTRLUBU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"BI 1482694
Olmutinib
HM61713
HM-61713",,,www.icoa.fr/pkidb/static/img/mol/Olmutinib.svg
Omipalisib,nan,1,GlaxosmithKline,'ZIG',3l08,1,1,505.1,4.8,107,7,1,6,nan,"PIK3CA
MTOR",Atypical,"Smiles=COc1c(cc(cn1)c2ccc3c(c2)c(ccn3)c4ccnnc4)NS(=O)(=O)c5ccc(cc5F)F
InChiKey=CGBJSGAELGCMKE-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Omipalisib
GSK2126458",,,www.icoa.fr/pkidb/static/img/mol/Omipalisib.svg
Orantinib,nan,3,Pfizer,'SU6',4jlc 5yvc,1,0,310.1,3.1,82.2,2,3,4,nan,"KDR
PDGFRB
FGFR1",Tyr,"Smiles=Cc1c(c([nH]c1/C=C\2/c3ccccc3NC2=O)C)CCC(=O)O
InChiKey=NHFDRBXTEDBWCZ-ZROIWOOFSA-N",nan,nan,Achiral Molecule,"TSU-68
SU-6668
Orantinib",,,www.icoa.fr/pkidb/static/img/mol/Orantinib.svg
Osimertinib,Tagrisso,4,Astrazeneca,'YY3',4zau,1,0,499.3,4.5,87.6,8,2,10,"Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.",EGFR,Tyr,"Smiles=Cn1cc(c2c1cccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N(C)CCN(C)C)NC(=O)C=C
InChiKey=DUYJMQONPNNFPI-UHFFFAOYSA-N",2015,US-8946235-B2,Achiral Molecule,"Tagrisso
Osimertinib
AZD-9291",Y,,www.icoa.fr/pkidb/static/img/mol/Osimertinib.svg
Pacritinib,nan,3,Cell Therapeutics,'6T3',5lbz,nan,0,472.2,5,68.7,7,1,4,nan,JAK2,Tyr,"Smiles=c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5
InChiKey=HWXVIOGONBBTBY-ONEGZZNKSA-N",nan,nan,Achiral Molecule,"ONX-0803
SB-1518
SB1518
Pacritinib",,,www.icoa.fr/pkidb/static/img/mol/Pacritinib.svg
Palbociclib,Ibrance,4,Pfizer,'LQQ',2euf 5l2i,1,0,447.2,3,105,9,2,5,"Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.","CDK4
CDK6",CMGC,"Smiles=Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5
InChiKey=AHJRHEGDXFFMBM-UHFFFAOYSA-N",2015,US-6936612-B2,Achiral Molecule,"Ibrance
Palbociclib
PD-0332991",Y,263-266,www.icoa.fr/pkidb/static/img/mol/Palbociclib.svg
Pamapimod,nan,2,Hoffmann-La Roche,'FLW',3flw,1,0,406.1,1.9,109.5,8,3,8,nan,"MAPK14
MAPK11",CMGC,"Smiles=Cn1c2c(cc(c1=O)Oc3ccc(cc3F)F)cnc(n2)NC(CCO)CCO
InChiKey=JYYLVUFNAHSSFE-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"R-1503
JTT-705
Pamapimod
Ro-4402257",,,www.icoa.fr/pkidb/static/img/mol/Pamapimod.svg
Panulisib,nan,1,Piramal Enterprises,NaN,NaN,nan,1,527.2,4.8,134.5,9,1,3,nan,"PIK3CA
MTOR",Atypical,"Smiles=CC(C)(C#N)c1ccc(cn1)n2c3c4cc(ccc4ncc3n(c2=NC#N)C)c5cc(c(nc5)N)C(F)(F)F
InChiKey=VJLRLTSXTLICIR-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,,,,www.icoa.fr/pkidb/static/img/mol/Panulisib.svg
Parsaclisib,nan,2,Incyte Corporation,NaN,NaN,nan,0,432.1,3.1,107.9,7,2,5,"Parsaclisib (INCB050465) is a PI3Kδ inhibitor that was developed by Incyte Corporation as an antineoplastic and immunomodulatory agent, as claimed in their patent WO2014134426A1 [1]. The chemical structure is one of those claimed in patent WO2013033569A1, but it is not clear which example it is from a mixture of diastereoisomers 345-348 (although 347 and 348 had the highest inhibitory potency vs. PI3Kδ and 347 was tested in vivo [2].",nan,,"Smiles=CCOc1c(cc(c(c1[C@H]2CC(=O)NC2)F)Cl)[C@H](C)n3c4c(c(n3)C)c(ncn4)N
InChiKey=ZQPDJCIXJHUERQ-QWRGUYRKSA-N",nan,nan,nan,INCB050465,,,www.icoa.fr/pkidb/static/img/mol/Parsaclisib.svg
Pazopanib,Votrient,4,GlaxoSmithKline,NaN,NaN,1,0,437.2,3.1,119,8,2,5,Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy),"FLT1
KDR
FLT4
PDGFRA
PDGFRB
KIT
FGFR3
ITK
FGFR1",Tyr,"Smiles=Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C
InChiKey=CUIHSIWYWATEQL-UHFFFAOYSA-N",2009,US-7105530-B2,Achiral Molecule,"Votrient
Pazopanib
GW786034",Y,,www.icoa.fr/pkidb/static/img/mol/Pazopanib.svg
Peficitinib,nan,3,Astellas Pharma,'9T6',6aah 6aaj 6aak 6aam,nan,0,326.2,2,104,4,4,3,nan,"JAK1
JAK2
JAK3
TYK2",Tyr,"Smiles=c1c[nH]c2c1c(c(cn2)C(=O)N)N[C@@H]3[C@@H]4C[C@@H]5C[C@H]3C[C@@](C5)(C4)O
InChiKey=DREIJXJRTLTGJC-ZKVNVPQCSA-N",nan,nan,Racemic Mixture,"ASP015K
ASP015K hydrobromide",,,www.icoa.fr/pkidb/static/img/mol/Peficitinib.svg
Pelitinib,nan,2,Wyeth,'93J',5vcw,1,1,467.2,5.1,90.3,6,2,8,nan,"EGFR
ERBB2",Tyr,"Smiles=CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)F
InChiKey=WVUNYSQLFKLYNI-AATRIKPKSA-N",nan,nan,Achiral Molecule,"WAY-EKB-569
EKB-569
Pelitinib",,,www.icoa.fr/pkidb/static/img/mol/Pelitinib.svg
Pexidartinib,Turalio,4,Daiichi Sankyo,'P31',4r7h,2,1,417.1,5.2,66.5,4,2,5,"On august 2019, FDA approved pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor","FLT3
KIT
CSF1R",Tyr,"Smiles=c1cc(ncc1Cc2c[nH]c3c2cc(cn3)Cl)NCc4ccc(nc4)C(F)(F)F
InChiKey=JGWRKYUXBBNENE-UHFFFAOYSA-N",2019,nan,Achiral Molecule,"CML-261
Pexidartinib
PLX3397",Y,,www.icoa.fr/pkidb/static/img/mol/Pexidartinib.svg
Pexmetinib,nan,1,Array BioPharma,NaN,NaN,nan,2,556.3,6.1,106.2,7,3,8,nan,"MAPK14
TEK","Tyr
CMGC","Smiles=Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)NCc3cc(ccc3Oc4ccc5c(c4)cnn5CCO)F
InChiKey=LNMRSSIMGCDUTP-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,,,,www.icoa.fr/pkidb/static/img/mol/Pexmetinib.svg
Pictilisib,nan,2,Hoffmann-La Roche,'GD9',2wxp 2y3a 3dbs,1,1,513.2,2.1,107.6,9,1,5,nan,"PIK3CA
PIK3CB
PIK3CD
PIK3CG",Atypical,"Smiles=CS(=O)(=O)N1CCN(CC1)Cc2cc3c(s2)c(nc(n3)c4cccc5c4cn[nH]5)N6CCOCC6
InChiKey=LHNIIDJUOCFXAP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"RG-7321
GDC-0941
Pictilisib",,,www.icoa.fr/pkidb/static/img/mol/Pictilisib.svg
Pilaralisib,nan,2,Sanofi,NaN,NaN,nan,1,540.1,4.5,148.3,8,4,8,nan,"PIK3CA
PIK3CB
PIK3CD
PIK3CG",Atypical,"Smiles=CC(C)(C(=O)Nc1cccc(c1)S(=O)(=O)Nc2c(nc3ccccc3n2)Nc4cc(ccc4Cl)OC)N
InChiKey=QINPEPAQOBZPOF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Pilaralisib
SAR-245408
XL-147",,,www.icoa.fr/pkidb/static/img/mol/Pilaralisib.svg
Pimasertib,nan,2,Merck,NaN,NaN,nan,0,431,1.7,94.5,5,4,6,nan,"MAP2K1
MAP2K2",STE,"Smiles=c1cc(c(cc1I)F)Nc2cnccc2C(=O)NC[C@@H](CO)O
InChiKey=VIUAUNHCRHHYNE-JTQLQIEISA-N",nan,nan,Single Stereoisomer,"MSC1936369A; AS703026; EMD 1036239
AS-703026
MSC-1936369B
EMD 1036239
Pimasertib",,,www.icoa.fr/pkidb/static/img/mol/Pimasertib.svg
Ponatinib,Iclusig,4,Ariad Pharmaceuticals,'0LI',3ik3 3oxz 3zos 4c8b 4qrc 4tyj 4u0i 4uxq 4v01 4v04 6eg9,2,1,532.2,4.5,65.8,6,1,4,"Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.","ABL1
BCR
KIT
RET
TEK
FLT3
FGFR1
FGFR2
FGFR3
FGFR4
LCK
SRC
LYN
KDR
PDGFRA","Atypical
Tyr","Smiles=Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C
InChiKey=PHXJVRSECIGDHY-UHFFFAOYSA-N",2012,US-8114874-B2,Achiral Molecule,"Iclusig
AP-24534
Ponatinib",Y,,www.icoa.fr/pkidb/static/img/mol/Ponatinib.svg
Poziotinib,nan,2,Hanmi Pharmaceutical,NaN,NaN,nan,1,490.1,5.4,76.6,6,1,6,nan,EGFR,Tyr,"Smiles=COc1cc2c(cc1OC3CCN(CC3)C(=O)C=C)c(ncn2)Nc4ccc(c(c4F)Cl)Cl
InChiKey=LPFWVDIFUFFKJU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"NOV-120101
Poziotinib
HM-781-36B",,,www.icoa.fr/pkidb/static/img/mol/Poziotinib.svg
Pralsetinib,nan,1.5,Blueprint Medicines,NaN,NaN,nan,1,533.3,4.2,135.5,9,3,8,"Pralsetinib, also known as BLU-667, is a highly potent, selective, next generation RET inhibitor. BLU-667 is a potent and selective inhibitor of RET mutations, fusions, and predicted resistant mutants. RET fusions are key drivers of multiple cancers, including lung and thyroid cancer, and our research suggests that RET also plays a key role in some colon and breast cancers. By simultaneously targeting the primary driver and predicted resistant mutants that render cancer cells insensitive to treatment with currently approved drugs",nan,,"Smiles=Cc1[nH]nc(c1)Nc2nc(nc(c2)C)[C@H]3CC[C@@](CC3)(OC)C(=O)N[C@H](c4cnc(cc4)n5ncc(c5)F)C
InChiKey=GBLBJPZSROAGMF-BATDWUPUSA-N",nan,nan,nan,BLU-667,,,www.icoa.fr/pkidb/static/img/mol/Pralsetinib.svg
Prexasertib,nan,2,Eli Lilly,NaN,NaN,nan,0,365.2,2.2,134.8,8,3,8,nan,"CHEK1
CHEK2",CAMK,"Smiles=COc1cccc(c1c2cc(n[nH]2)Nc3cnc(cn3)C#N)OCCCN
InChiKey=DOTGPNHGTYJDEP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"LY-2606368
Prexasertib",,,www.icoa.fr/pkidb/static/img/mol/Prexasertib.svg
Pyrotinib,nan,3,Hengrui Therapeutics,NaN,NaN,nan,2,582.2,6.5,112.4,8,2,10,nan,"EGFR
ERBB2",Tyr,"Smiles=CCOc1cc2c(cc1NC(=O)/C=C/[C@H]3CCCN3C)c(c(cn2)C#N)Nc4ccc(c(c4)Cl)OCc5ccccn5
InChiKey=SADXACCFNXBCFY-IYNHSRRRSA-N",nan,nan,Single Stereoisomer,SHR1258,,,www.icoa.fr/pkidb/static/img/mol/Pyrotinib.svg
Quizartinib,nan,3,Ambit Biosciences,'P30',4rt7 4xuf,2,2,560.2,5.9,106.2,9,2,7,nan,"FLT3
CSF1R
KIT",Tyr,"Smiles=CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6
InChiKey=CVWXJKQAOSCOAB-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"ASP-2689
AC220
Quizartinib
AC010220
AC-220",,,www.icoa.fr/pkidb/static/img/mol/Quizartinib.svg
Rabusertib,nan,2,Eli Lilly,NaN,NaN,nan,0,435.1,2.9,97.4,6,3,5,nan,CHEK1,CAMK,"Smiles=Cc1cc(c(cc1Br)NC(=O)Nc2cnc(cn2)C)OC[C@@H]3CNCCO3
InChiKey=SYYBDNPGDKKJDU-ZDUSSCGKSA-N",nan,nan,Single Stereoisomer,"Rabusertib
LY-2603618
IC-83",,,www.icoa.fr/pkidb/static/img/mol/Rabusertib.svg
Radotinib,nan,3,Il-Yang Pharmaceutical,NaN,NaN,nan,2,530.2,5.8,110.5,8,2,6,"Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.","ABL1
PDGFRB",Tyr,"Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cnccn3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F
InChiKey=DUPWHXBITIZIKZ-UHFFFAOYSA-N",nan,nan,nan,"SUPEC
IY5511HCL",,,www.icoa.fr/pkidb/static/img/mol/Radotinib.svg
Ralimetinib,nan,2,Eli Lilly,NaN,NaN,nan,1,420.2,5.6,85.4,5,2,3,nan,"MAPK14
MAPK11",CMGC,"Smiles=CC(C)(C)Cn1c2c(ccc(n2)c3c(nc([nH]3)C(C)(C)C)c4ccc(cc4)F)nc1N
InChiKey=XPPBBJCBDOEXDN-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"LY-2228820
LY-22288220
Ralimetinib",,,www.icoa.fr/pkidb/static/img/mol/Ralimetinib.svg
Ravoxertinib,nan,1,Genentech,'6QB',5k4i 5k4j 6oph,nan,0,440.1,3.2,97.9,8,2,6,nan,nan,,"Smiles=Cn1c(ccn1)Nc2nccc(n2)c3ccn(c(=O)c3)[C@H](CO)c4ccc(c(c4)F)Cl
InChiKey=RZUOCXOYPYGSKL-GOSISDBHSA-N",nan,nan,Single Stereoisomer,"Ravoxertinib
RG-7842
GDC-0994",,,www.icoa.fr/pkidb/static/img/mol/Ravoxertinib.svg
Rebastinib,nan,2,Deciphera Pharmaceuticals,'919',3qri 3qrj 5g6v 6cnh 6mwe,2,2,553.2,6,123.1,7,3,6,nan,"FLT3
TEK
KDR
LYN
BCR
ABL1
NTRK1","Atypical
Tyr","Smiles=CC(C)(C)c1cc(n(n1)c2ccc3c(c2)cccn3)NC(=O)Nc4ccc(cc4F)Oc5ccnc(c5)C(=O)NC
InChiKey=WVXNSAVVKYZVOE-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"DP-1919
DP-1919
DCC-2036
Rebastinib",,,www.icoa.fr/pkidb/static/img/mol/Rebastinib.svg
Recilisib,Ex-RAD,1,Onconova Therapeutics,NaN,NaN,nan,0,336,3.6,71.4,3,1,5,nan,nan,,"Smiles=c1cc(ccc1CS(=O)(=O)/C=C/c2ccc(cc2)C(=O)O)Cl
InChiKey=KBEKQQJUNVQLDZ-MDZDMXLPSA-N",nan,nan,Achiral Molecule,"Ex-RAD
ON-01210
ON-01210.Na
Recilisib",,,www.icoa.fr/pkidb/static/img/mol/Recilisib.svg
Refametinib,nan,2,Bayer,'VRA',3e8n,nan,1,572,3.5,107.9,6,4,9,nan,MAP2K1,STE,"Smiles=COc1cc(c(c(c1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)Nc3ccc(cc3F)I)F)F
InChiKey=RDSACQWTXKSHJT-NSHDSACASA-N",nan,nan,Single Stereoisomer,"BAY-86-9766
Refametinib
RDEA-119",,,www.icoa.fr/pkidb/static/img/mol/Refametinib.svg
Regorafenib,Stivarga,4,Bayer,NaN,NaN,2,1,482.1,5.7,92.3,4,3,5,"Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.","FLT1
KDR
FLT4
KIT
PDGFRA
PDGFRB
FGFR1
FGFR2
TEK
DDR2
NTRK1
EPHA2
RAF1
BRAF
MAPK11
FRK
ABL1
RET","TKL
Tyr
CMGC","Smiles=CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl
InChiKey=FNHKPVJBJVTLMP-UHFFFAOYSA-N",2012,US-7351834-B1,Achiral Molecule,"Stivarga
Regorafenib
BAY-734506 monohydrate
BAY-73-4506",Y,,www.icoa.fr/pkidb/static/img/mol/Regorafenib.svg
Ribociclib,Kisqali,4,Novartis,'6ZZ',5l2t,1,0,434.3,2.8,91.2,8,2,5,"Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.","CDK4
CDK6",CMGC,"Smiles=CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5
InChiKey=RHXHGRAEPCAFML-UHFFFAOYSA-N",2017,US-8324225-B2,Achiral Molecule,"Ribociclib
LEE-011
NVP-LEE011",Y,,www.icoa.fr/pkidb/static/img/mol/Ribociclib.svg
Rigosertib,nan,3,Onconova Therapeutics,'6FS',5j18 5j2r 5ov7,3,0,451.1,2.8,120.4,8,2,11,nan,"PIK3CA
PLK1","Atypical
Other","Smiles=COc1ccc(cc1NCC(=O)O)CS(=O)(=O)/C=C/c2c(cc(cc2OC)OC)OC
InChiKey=OWBFCJROIKNMGD-BQYQJAHWSA-N",nan,nan,Achiral Molecule,"Rigosertib
ON-01910",,,www.icoa.fr/pkidb/static/img/mol/Rigosertib.svg
Ripasudil,nan,2,Kowa Pharmaceutical,NaN,NaN,nan,0,323.1,1.7,62.3,4,1,2,nan,nan,,"Smiles=C[C@H]1CNCCCN1S(=O)(=O)c2cccc3c2c(cnc3)F
InChiKey=QSKQVZWVLOIIEV-NSHDSACASA-N",nan,nan,nan,RIPASUDIL,,,www.icoa.fr/pkidb/static/img/mol/Ripasudil.svg
Ripretinib,nan,3,Deciphera Pharmaceuticals,NaN,NaN,nan,2,509.1,5.7,88,5,3,5,"Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFRα kinase inhibitor being developed by Dicephera Pharmaceuticals. It is in clinical development for the treatment of malignancies that are driven by KIT and/or PDGFRα, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors.",nan,,"Smiles=CCn1c2cc(ncc2cc(c1=O)c3cc(c(cc3Br)F)NC(=O)Nc4ccccc4)NC
InChiKey=CEFJVGZHQAGLHS-UHFFFAOYSA-N",nan,nan,nan,"DCC-2618
RIPRETINIB",,,www.icoa.fr/pkidb/static/img/mol/Ripretinib.svg
Riviciclib,nan,2,Piramal Enterprises,NaN,NaN,nan,0,401.1,3.3,94.1,6,3,3,nan,"CDK1
CDK4
CDK9",CMGC,"Smiles=CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O
InChiKey=QLUYMIVVAYRECT-OCCSQVGLSA-N",nan,nan,Racemic Mixture,,,,www.icoa.fr/pkidb/static/img/mol/Riviciclib.svg
Rivoceranib,nan,1,Advenchen Laboratories,NaN,NaN,nan,0,493.2,4.2,145.1,7,3,6,Rivoceranib Mesylate is a novel selective inhibitor of vascular endothelial growth factor receptor 2 (vegfr2),nan,,"Smiles=CS(=O)(=O)O.c1cc(c(nc1)NCc2ccncc2)C(=O)Nc3ccc(cc3)C4(CCCC4)C#N
InChiKey=FYJROXRIVQPKRY-UHFFFAOYSA-N",nan,nan,nan,YN-968D1,,,www.icoa.fr/pkidb/static/img/mol/Rivoceranib.svg
Rociletinib,nan,3,Clovis Oncology,'8JC',5xdk 5xdl,1,1,555.2,4.8,111.7,8,3,8,nan,EGFR,Tyr,"Smiles=CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F
InChiKey=HUFOZJXAKZVRNJ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CNX-419
AVL-301
CO-1686
Rociletinib",,,www.icoa.fr/pkidb/static/img/mol/Rociletinib.svg
Rogaratinib,nan,2,Bayer,NaN,NaN,nan,0,466.2,2.6,107,9,2,6,Rogaratinib (BAY-1163877) is a FGFR-selective kinase inhibitor that is being investigated for antineoplastic activity.,nan,,"Smiles=Cc1cc2cc(sc2c(c1)OC)c3c(c(n4c3c(ncn4)N)CN5CCNC(=O)C5)COC
InChiKey=HNLRRJSKGXOYNO-UHFFFAOYSA-N",nan,nan,nan,"ROGARATINIB
BAY 1163877",,,www.icoa.fr/pkidb/static/img/mol/Rogaratinib.svg
Roniciclib,nan,2,Bayer,NaN,NaN,nan,0,430.1,4,108.2,7,3,7,nan,"CDK1
CDK2
CDK4
CDK9",CMGC,"Smiles=C[C@H]([C@@H](C)Oc1c(cnc(n1)Nc2ccc(cc2)[S@](=N)(=O)C3CC3)C(F)(F)F)O
InChiKey=UELYDGOOJPRWGF-SRQXXRKNSA-N",nan,nan,Single Stereoisomer,,,,www.icoa.fr/pkidb/static/img/mol/Roniciclib.svg
Ruboxistaurin,Arxxant,3,Eli Lilly,'LY4',1uu3 2j2i,nan,0,468.2,3.5,68.5,6,1,2,nan,nan,,"Smiles=CN(C)C[C@@H]1CCn2cc(c3c2cccc3)C4=C(c5cn(c6c5cccc6)CCO1)C(=O)NC4=O
InChiKey=ZCBUQCWBWNUWSU-SFHVURJKSA-N",nan,nan,Single Stereoisomer,"Arxxant
LY-333531
Ruboxistaurin",,,www.icoa.fr/pkidb/static/img/mol/Ruboxistaurin.svg
Ruxolitinib,Jakafi,4,Incyte Corporation,'RXT',4u5j,1,0,306.2,3.5,83.2,5,1,4,"Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).","JAK1
JAK2",Tyr,"Smiles=c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC4
InChiKey=HFNKQEVNSGCOJV-OAHLLOKOSA-N",2011,US-7598257-B2,Single Stereoisomer,"Jakavi
INCB-018424
Ruxolitinib",Y,,www.icoa.fr/pkidb/static/img/mol/Ruxolitinib.svg
Samotolisib,nan,2,Eli Lilly,NaN,NaN,nan,0,406.2,3.2,82.2,7,1,5,"LY3023414 is a dual inhibitor of phosphoinositide 3-kinase α (PI3Kα) and the serine/threonine kinase mTOR (mechanistic target of rapamycin), with potential antineoplastic activity.",nan,,"Smiles=C[C@@H](Cn1c2c3cc(ccc3ncc2n(c1=O)C)c4cc(cnc4)C(C)(C)O)OC
InChiKey=ACCFLVVUVBJNGT-AWEZNQCLSA-N",nan,nan,nan,"LY-3023414
LY 3023414
WHO 10889
LY3023414",,,www.icoa.fr/pkidb/static/img/mol/Samotolisib.svg
Sapanisertib,nan,2,Takeda,'FE5',6gvf,nan,0,309.1,2.4,121.7,8,2,2,nan,MTOR,Atypical,"Smiles=CC(C)n1c2c(c(n1)c3ccc4c(c3)nc(o4)N)c(ncn2)N
InChiKey=GYLDXIAOMVERTK-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MLN-0128
Sapanisertib
TAK-228",,,www.icoa.fr/pkidb/static/img/mol/Sapanisertib.svg
Sapitinib,nan,2,Astrazeneca,NaN,NaN,nan,0,473.2,3.8,88.6,7,2,7,nan,"EGFR
ERBB2
ERBB4
ERBB3",Tyr,"Smiles=CNC(=O)CN1CCC(CC1)Oc2cc3c(cc2OC)ncnc3Nc4cccc(c4F)Cl
InChiKey=DFJSJLGUIXFDJP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Sapitinib
AZD-8931",,,www.icoa.fr/pkidb/static/img/mol/Sapitinib.svg
Saracatinib,nan,3,Astrazeneca,'H8H',2h8h 4qmx 5vcx 5vd3,1,1,541.2,3.9,90.4,10,1,8,nan,"SRC
ABL1",Tyr,"Smiles=CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl
InChiKey=OUKYUETWWIPKQR-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"AZD-0530
Saracatinib
AZ-10353926",,,www.icoa.fr/pkidb/static/img/mol/Saracatinib.svg
Savolitinib,nan,3,Astrazeneca,'V0L',5lbw 6sde,nan,0,345.1,1.9,91.6,9,0,3,nan,MET,Tyr,"Smiles=C[C@@H](c1ccc2nccn2c1)n3c4c(ncc(n4)c5cnn(c5)C)nn3
InChiKey=XYDNMOZJKOGZLS-NSHDSACASA-N",nan,nan,Single Stereoisomer,"AZD-6094
Savolitinib
HMPL-504
AZD6094",,,www.icoa.fr/pkidb/static/img/mol/Savolitinib.svg
Selatinib,nan,1,Qilu Pharmaceutical,NaN,NaN,nan,2,564.1,6.5,89.3,7,2,11,nan,"EGFR
ERBB2",Tyr,"Smiles=CS(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F
InChiKey=OAMVGUFHZPRXOM-UHFFFAOYSA-N",nan,nan,nan,,,,www.icoa.fr/pkidb/static/img/mol/Selatinib.svg
Seliciclib,nan,2,Cyclacel pharmaceuticals,'RRC',1unl 1ygk 2a4l 3ddq,1,0,354.2,3.2,87.9,7,3,8,nan,"CDK2
CDK7
CDK9",CMGC,"Smiles=CC[C@H](CO)Nc1nc(NCc2ccccc2)c3ncn(C(C)C)c3n1
InChiKey=BTIHMVBBUGXLCJ-OAHLLOKOSA-N",nan,nan,Single Stereoisomer,"Seliciclib
CYC-202
AL-39256",,,www.icoa.fr/pkidb/static/img/mol/Seliciclib.svg
Selonsertib,nan,2,Gilead Sciences,'NJV',6oyt,nan,0,445.2,4.7,90.5,7,1,6,nan,MAP3K5,STE,"Smiles=Cc1cc(c(cc1n2cc(nc2)C3CC3)C(=O)Nc4cccc(n4)c5nncn5C(C)C)F
InChiKey=YIDDLAAKOYYGJG-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GS-4997
Selonsertib",,,www.icoa.fr/pkidb/static/img/mol/Selonsertib.svg
Selumetinib,nan,3,Astrazeneca,'3EW',4u7z,3,0,456,3.5,88.4,6,3,6,nan,"MAP2K1
MAP2K2",STE,"Smiles=Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO
InChiKey=CYOHGALHFOKKQC-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"ARRY-142886
AZD-6244
ARRY-886
Selumetinib",,,www.icoa.fr/pkidb/static/img/mol/Selumetinib.svg
Semaxanib,nan,3,Sugen,'X2M',2x2m,1,0,238.1,3.1,44.9,1,2,1,Investigated for use/treatment in colorectal cancer and lung cancer.,KDR,Tyr,"Smiles=Cc1cc([nH]c1/C=C\2/c3ccccc3NC2=O)C
InChiKey=WUWDLXZGHZSWQZ-WQLSENKSSA-N",nan,nan,Achiral Molecule,"SU-5416
Semaxinib
Semaxanib",,,www.icoa.fr/pkidb/static/img/mol/Semaxanib.svg
Silmitasertib,nan,2,Senhwa Biosciences,'3NG',3nga 3pe1 5o11 6fyl 6fyp 6fyv 6hmb 6isj 6k3l 6khd 6khe 6khf 6p5s,1,0,349.1,4.9,75.1,4,2,3,nan,"CSNK2A1
CSNK2A2",Other,"Smiles=c1cc(cc(c1)Cl)Nc2c3ccncc3c4ccc(cc4n2)C(=O)O
InChiKey=MUOKSQABCJCOPU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Silmitasertib
CX-4945",,,www.icoa.fr/pkidb/static/img/mol/Silmitasertib.svg
Simotinib,nan,3,Advenchen Laboratories,NaN,NaN,nan,1,500.2,4.4,78,8,1,7,nan,EGFR,Tyr,"Smiles=COc1cc2c(cc1OCCN3CC4(CC4)C5(C3)OCCO5)c(ncn2)Nc6ccc(c(c6)Cl)F
InChiKey=OXWUWXCJDBRCCG-UHFFFAOYSA-N",nan,nan,nan,SIM-6802,,,www.icoa.fr/pkidb/static/img/mol/Simotinib.svg
Sitravatinib,nan,3,Mirati Therapeutics,NaN,NaN,nan,2,629.2,6.5,114.5,8,3,12,nan,"RET
DDR2
NTRK1
NTRK2
NTRK3",Tyr,"Smiles=COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
InChiKey=WLAVZAAODLTUSW-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MGCD516
Sitravatinib",,,www.icoa.fr/pkidb/static/img/mol/Sitravatinib.svg
Solcitinib,nan,2,GlaxoSmithKline,NaN,NaN,nan,0,389.2,3.2,79.6,5,1,4,nan,JAK1,Tyr,"Smiles=CC1(CN(C1)C(=O)c2ccc(cc2)c3cccc4n3nc(n4)NC(=O)C5CC5)C
InChiKey=MPYACSQFXVMWNO-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GLPG-0788
GSK2586184A
Solcitinib
GSK2586184
G-154578
GLPG-0778",,,www.icoa.fr/pkidb/static/img/mol/Solcitinib.svg
Sonolisib,nan,2,Cascadian Therapeutics,NaN,NaN,nan,1,525.2,3.1,119.4,9,1,8,nan,"PIK3CA
PIK3CB
PIK3CG",Atypical,"Smiles=CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C
InChiKey=QIUASFSNWYMDFS-NILGECQDSA-N",nan,nan,Single Stereoisomer,"Sonolisib
PX-866",,,www.icoa.fr/pkidb/static/img/mol/Sonolisib.svg
Sorafenib,Nexavar,4,Bayer,'BAX',1uwh 1uwj 3gcs 3heg 3rgf 3wze 4asd 5hi2,2,1,464.1,5.5,92.3,4,3,5,Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.,"BRAF
RAF1
FLT4
KDR
FLT3
PDGFRB
KIT
FGFR1
RET
FLT1","TKL
Tyr","Smiles=CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl
InChiKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N",2005,US-7235576-B1,Achiral Molecule,"Nexavar
Sorafenib
BAY-43-9006",Y,205.6,www.icoa.fr/pkidb/static/img/mol/Sorafenib.svg
Sotrastaurin,nan,2,Novartis,'LW4',3iw4,nan,0,438.2,2.4,94.2,6,2,3,nan,nan,,"Smiles=CN1CCN(CC1)c2nc3ccccc3c(n2)C4=C(C(=O)NC4=O)c5c[nH]c6c5cccc6
InChiKey=OAVGBZOFDPFGPJ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"AEB-071
NVP-AEB071
AEB071
Sotrastaurin",,,www.icoa.fr/pkidb/static/img/mol/Sotrastaurin.svg
Spebrutinib,nan,2,Celgene,NaN,NaN,nan,0,423.2,4.3,97.4,7,3,10,nan,BTK,Tyr,"Smiles=COCCOc1ccc(cc1)Nc2ncc(c(n2)Nc3cccc(c3)NC(=O)C=C)F
InChiKey=KXBDTLQSDKGAEB-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CC-292
AVL-292
Spebrutinib",,,www.icoa.fr/pkidb/static/img/mol/Spebrutinib.svg
Sunitinib,Sutent,4,Cp Pharmaceuticals,'B49',2y7j 3g0e 3g0f 3miy 3ti1 4agd 4ks8 4qmz 6nfy 6nfz 6ng0,1,0,398.2,3.3,77.2,3,3,7,For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.,"PDGFRB
FLT1
KIT
KDR
FLT4
FLT3
CSF1R
PDGFRA",Tyr,"Smiles=CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C
InChiKey=WINHZLLDWRZWRT-ATVHPVEESA-N",2006,US-6573293-B2,Achiral Molecule,"Sutent
Sunitinib
SU-11248
Sutent",Y,,www.icoa.fr/pkidb/static/img/mol/Sunitinib.svg
Tafetinib,nan,1,Nanjing Yoko Biomedical,NaN,NaN,nan,0,424.2,3.7,77.2,3,3,6,nan,"KDR
FLT4
FLT1",Tyr,"Smiles=CCN(CC)CCNC(=O)c1c([nH]c\2c1CCC/C2=C/3\c4cc(ccc4NC3=O)F)C
InChiKey=KGSRYTUWXUESJK-FXBPSFAMSA-N",nan,nan,nan,,,,www.icoa.fr/pkidb/static/img/mol/Tafetinib.svg
Talmapimod,nan,2,Scios inc,'469',3hub 3zsh,1,1,512.2,4,65.9,5,0,5,Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.,MAPK14,CMGC,"Smiles=C[C@@H]1CN([C@H](CN1C(=O)c2cc3c(cc2Cl)n(cc3C(=O)C(=O)N(C)C)C)C)Cc4ccc(cc4)F
InChiKey=ZMELOYOKMZBMRB-DLBZAZTESA-N",nan,nan,Single Stereoisomer,"Talmapimod
SCIO-469",,,www.icoa.fr/pkidb/static/img/mol/Talmapimod.svg
Tamatinib,nan,2,Rigel Pharmaceuticals,'585',3fqs 3piy,1,0,470.2,3.6,128.8,10,3,7,nan,SYK,Tyr,"Smiles=CC1(C(=O)Nc2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)C
InChiKey=NHHQJBCNYHBUSI-UHFFFAOYSA-N",nan,nan,nan,R-406,,,www.icoa.fr/pkidb/static/img/mol/Tamatinib.svg
Tandutinib,nan,2,Takeda,NaN,NaN,nan,2,562.3,5,92.3,8,1,10,Investigated for use/treatment in leukemia (myeloid).,"FLT3
PDGFD","(*)
Tyr","Smiles=CC(C)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c3c4cc(c(cc4ncn3)OCCCN5CCCCC5)OC
InChiKey=UXXQOJXBIDBUAC-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Tandutinib
MLN-0518
CT-53518
MLN-518",,,www.icoa.fr/pkidb/static/img/mol/Tandutinib.svg
Tanzisertib,nan,2,Celgene,'KBI',3tti,1,0,448.2,3.7,97.1,8,3,5,nan,MAPK8,CMGC,"Smiles=c1c(c(c(cc1F)F)Nc2n(c3nc(ncc3n2)N[C@H]4CC[C@@H](CC4)O)[C@@H]5COCC5)F
InChiKey=IBGLGMOPHJQDJB-IHRRRGAJSA-N",nan,nan,Single Stereoisomer,"Tanzisertib
JNK-930
CC-930",,,www.icoa.fr/pkidb/static/img/mol/Tanzisertib.svg
Tarloxotinib,nan,2,Threshold Pharmaceuticals,NaN,NaN,nan,1,679,1.6,140.8,9,2,9,nan,EGFR,Tyr,"Smiles=Cn1cnc(c1C[N+](C)(C)C/C=C/C(=O)Nc2cc3c(cn2)ncnc3Nc4ccc(c(c4)Br)Cl)[N+](=O)[O-].[Br-]
InChiKey=WAKIMVYUBWMMHJ-FXRZFVDSSA-N",nan,nan,nan,,,,www.icoa.fr/pkidb/static/img/mol/Tarloxotinib.svg
Taselisib,nan,3,Hoffmann-La Roche,'799',5t8f,1,0,460.2,3.2,118.7,9,1,5,nan,"PIK3CA
PIK3CD
PIK3CG",Atypical,"Smiles=Cc1nc(n(n1)C(C)C)c2cn3c(n2)-c4ccc(cc4OCC3)c5cnn(c5)C(C)(C)C(=O)N
InChiKey=BEUQXVWXFDOSAQ-UHFFFAOYSA-N",nan,nan,Racemic Mixture,"RG-7604
Taselisib
GDC-0032",,,www.icoa.fr/pkidb/static/img/mol/Taselisib.svg
Telatinib,nan,2,Bayer,NaN,NaN,nan,0,409.1,4,102.2,7,2,6,nan,"KDR
FLT4",Tyr,"Smiles=CNC(=O)c1cc(ccn1)COc2c3c(cco3)c(nn2)Nc4ccc(cc4)Cl
InChiKey=QFCXANHHBCGMAS-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"BAY-57-9352
Telatinib
BAY-579352",,,www.icoa.fr/pkidb/static/img/mol/Telatinib.svg
Tepotinib,nan,2,Merck,'3E8',4r1v,1,0,492.2,4,96.9,8,0,7,nan,MET,Tyr,"Smiles=CN1CCC(CC1)COc2cnc(nc2)c3cccc(c3)Cn4c(=O)ccc(n4)c5cccc(c5)C#N
InChiKey=AHYMHWXQRWRBKT-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MSC-2156119
Tepotinib
MSC-2156119J
EMD-1214063",,,www.icoa.fr/pkidb/static/img/mol/Tepotinib.svg
Tesevatinib,nan,2,Kadmon Corporation,NaN,NaN,nan,1,490.1,5.8,59.5,6,1,6,nan,"EGFR
ERBB2
KDR
FLT4
EPHB4",Tyr,"Smiles=CN1C[C@H]2C[C@H](C[C@H]2C1)COc3cc4c(cc3OC)c(ncn4)Nc5ccc(c(c5F)Cl)Cl
InChiKey=HVXKQKFEHMGHSL-QKDCVEJESA-N",nan,nan,Racemic Mixture,"Tesevatinib
XL-647
KD-020
KD-019",,,www.icoa.fr/pkidb/static/img/mol/Tesevatinib.svg
Tivantinib,nan,3,Daiichi Sankyo,'TIV',5cb4,nan,0,369.1,3.6,66.9,3,2,2,nan,MET,Tyr,"Smiles=c1ccc2c(c1)c(c[nH]2)[C@H]3[C@@H](C(=O)NC3=O)c4cn5c6c4cccc6CCC5
InChiKey=UCEQXRCJXIVODC-PMACEKPBSA-N",nan,nan,Single Stereoisomer,"ARQ-197
Tivantinib",,,www.icoa.fr/pkidb/static/img/mol/Tivantinib.svg
Tivozanib,nan,4,Aveo Pharmaceuticals,'AV9',4ase,2,1,454.1,5.6,107.7,7,2,6,Tivozanib is an oral VEGF receptor tyrosine kinase inhibitor.,"FLT1
KDR
FLT4",Tyr,"Smiles=Cc1cc(no1)NC(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC
InChiKey=SPMVMDHWKHCIDT-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"AV-951
Tivozanib
Kil-8951
Kil8951
ASP-4130
KRN-951",N,,www.icoa.fr/pkidb/static/img/mol/Tivozanib.svg
Toceranib,nan,0,Pfizer,NaN,NaN,nan,0,396.2,3.1,77.2,3,3,5,nan,KIT,KIT,"Smiles=Cc1c([nH]c(c1C(=O)NCCN2CCCC2)C)/C=C\3/c4cc(ccc4NC3=O)F
InChiKey=SRSGVKWWVXWSJT-ATVHPVEESA-N",nan,nan,Achiral Molecule,"PHA-291639
Toceranib",,,www.icoa.fr/pkidb/static/img/mol/Toceranib.svg
Tofacitinib,Xeljanz,4,Pfizer,'MI1',3eyg 3fup 3lxk 3lxn 4oti,1,0,312.2,1.5,88.9,5,1,3,"For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.","JAK1
JAK2
JAK3
TYK2",Tyr,"Smiles=C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CC#N
InChiKey=UJLAWZDWDVHWOW-YPMHNXCESA-N",2012,US-6956041-B2,Single Stereoisomer,"Tasocitinib
550
CP-690550
CP-690
Tofacitinib",Y,,www.icoa.fr/pkidb/static/img/mol/Tofacitinib.svg
Tomivosertib,nan,2,Effector Therapeutics,'N45',6ck6,nan,0,340.2,1.6,114.9,7,3,2,"Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling",nan,,"Smiles=Cc1cc(c(=O)n2c1C(=O)NC23CCCCC3)Nc4cc(ncn4)N
InChiKey=HKTBYUWLRDZAJK-UHFFFAOYSA-N",nan,nan,nan,NK1 AND MNK2,,,www.icoa.fr/pkidb/static/img/mol/Tomivosertib.svg
Tozasertib,nan,2,Merck,'VX6',2f4j 2xyn 3amb 3e5a 4af3 4b8m 4jbq 4zog 5wnm 6brj 6gr9,1,0,464.2,3.5,102.1,8,3,7,nan,"AURKA
AURKB
AURKC",Other,"Smiles=Cc1cc(n[nH]1)Nc2cc(nc(n2)Sc3ccc(cc3)NC(=O)C4CC4)N5CCN(CC5)C
InChiKey=GCIKSSRWRFVXBI-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"VX-680
MK-0457
Tozasertib
VX-68
MK-045",,,www.icoa.fr/pkidb/static/img/mol/Tozasertib.svg
Trametinib,Mekinist,4,GlaxoSmithKline,NaN,NaN,3,1,615.1,3.9,107.1,8,2,5,"Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","BRAF
MAP2K1
MAP2K2","TKL
STE","Smiles=Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5
InChiKey=LIRYPHYGHXZJBZ-UHFFFAOYSA-N",2013,US-7378423-B2,Achiral Molecule,"Mekinist
GSK1120212
Trametinib",Y,293-303,www.icoa.fr/pkidb/static/img/mol/Trametinib.svg
Trilaciclib,nan,2,G1 Therapeutics,NaN,NaN,nan,0,446.3,2.7,91.2,8,2,3,nan,"CDK4
CDK6",CMGC,"Smiles=CN1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O
InChiKey=PDGKHKMBHVFCMG-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"G1T28
Trilaciclib",,,www.icoa.fr/pkidb/static/img/mol/Trilaciclib.svg
Tucatinib,nan,2,Array BioPharma,NaN,NaN,nan,1,480.2,5.1,110.9,10,2,5,nan,ERBB2,Tyr,"Smiles=Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C
InChiKey=SDEAXTCZPQIFQM-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Tucatinib
ONT-380
ARRY-380",,,www.icoa.fr/pkidb/static/img/mol/Tucatinib.svg
Ulixertinib,nan,2,BioMed Valley Discoveries,'EVK',6gdq,nan,0,432.1,4.7,90,4,4,7,nan,"MAPK1
MAPK3",CMGC,"Smiles=CC(C)Nc1cc(c(cn1)Cl)c2cc([nH]c2)C(=O)N[C@H](CO)c3cccc(c3)Cl
InChiKey=KSERXGMCDHOLSS-LJQANCHMSA-N",nan,nan,Single Stereoisomer,"VRT752271
VRT-752271
BVD-523",,,www.icoa.fr/pkidb/static/img/mol/Ulixertinib.svg
Umbralisib,nan,3,TG Therapeutics,NaN,NaN,nan,2,571.2,6.7,109.1,8,1,6,nan,nan,,"Smiles=C[C@@H](c1c(c(=O)c2cc(ccc2o1)F)c3cccc(c3)F)n4c5c(c(n4)c6ccc(c(c6)F)OC(C)C)c(ncn5)N
InChiKey=IUVCFHHAEHNCFT-INIZCTEOSA-N",nan,nan,Single Stereoisomer,"Umbralisib
TGR-1202 base
RP-5264",,,www.icoa.fr/pkidb/static/img/mol/Umbralisib.svg
Upadacitinib,Rinvoq,4,Abbvie,NaN,NaN,nan,0,380.2,2.9,78.3,4,2,3,"On august 2019, FDA approved fedratinib to treat adults with moderately to severely active rheumatoid arthritis",JAK1,Tyr,"Smiles=CC[C@@H]1CN(C[C@@H]1c2cnc3n2c4cc[nH]c4nc3)C(=O)NCC(F)(F)F
InChiKey=WYQFJHHDOKWSHR-MNOVXSKESA-N",2019,nan,Single Stereoisomer,"ABT-494
Upadacitinib",Y,,www.icoa.fr/pkidb/static/img/mol/Upadacitinib.svg
Uprosertib,nan,2,GlaxoSmithKline,NaN,NaN,nan,0,428.1,3.6,86.1,5,2,6,nan,"AKT1
AKT2
AKT3",AGC,"Smiles=Cn1c(c(cn1)Cl)c2cc(oc2Cl)C(=O)N[C@@H](Cc3ccc(c(c3)F)F)CN
InChiKey=AXTAPYRUEKNRBA-JTQLQIEISA-N",nan,nan,Single Stereoisomer,"Uprosertib
GSK2141795C
GSK2141795",,,www.icoa.fr/pkidb/static/img/mol/Uprosertib.svg
Vactosertib,nan,1.5,MedPacto,NaN,NaN,nan,0,399.2,4.2,83.8,6,2,5,"Vactosertib (EW-7197) acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.",nan,,"Smiles=Cc1cccc(n1)c2c(nc([nH]2)CNc3ccccc3F)c4ccc5ncnn5c4
InChiKey=FJCDSQATIJKQKA-UHFFFAOYSA-N",nan,nan,nan,,,,www.icoa.fr/pkidb/static/img/mol/Vactosertib.svg
Vandetanib,Caprelsa;Zactima,4,Ipr Pharmaceuticals,'ZD6',2ivu,1.5,1,474.1,5,59.5,6,1,6,"Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.","VEGFA
EGFR
PTK6
TEK
RET","(*)
Tyr","Smiles=CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br
InChiKey=UHTHHESEBZOYNR-UHFFFAOYSA-N",2011,US-RE42353-E1,Achiral Molecule,"Caprelsa;Zactima
GNF-Pf-2188
ZD-6474
Vandetanib
ZD-64",Y,,www.icoa.fr/pkidb/static/img/mol/Vandetanib.svg
Varlitinib,nan,2.5,Array Biopharma,NaN,NaN,nan,1,466.1,5.2,93.5,9,2,6,Investigated for use/treatment in cancer/tumors (unspecified).,"EGFR
ERBB2",Tyr,"Smiles=C[C@@H]1COC(=N1)Nc2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5nccs5
InChiKey=UWXSAYUXVSFDBQ-CYBMUJFWSA-N",nan,nan,Single Stereoisomer,"ARRY-543
ASLAN-001
Varlitinib
ARRY-334543",,,www.icoa.fr/pkidb/static/img/mol/Varlitinib.svg
Vatalanib,nan,3,Novartis,NaN,NaN,nan,1,346.1,5,50.7,4,1,4,Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).,"FLT1
KDR
FLT4",Tyr,"Smiles=c1ccc2c(c1)c(nnc2Nc3ccc(cc3)Cl)Cc4ccncc4
InChiKey=YCOYDOIWSSHVCK-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"BAY-86-5127
PTK-787
NVP-PTK787
ZK-222584
K-222584
CGP-79787
PTK787
Vatalanib",,,www.icoa.fr/pkidb/static/img/mol/Vatalanib.svg
Vemurafenib,Zelboraf,4,Hoffmann-La Roche,'032',3og7 4rzv 5hes,1.5,1,489.1,5.5,91.9,4,2,7,"Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.",BRAF,TKL,"Smiles=CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(cc4)Cl)F
InChiKey=GPXBXXGIAQBQNI-UHFFFAOYSA-N",2011,US-7504509-B2,Achiral Molecule,"Zelboraf
Vemurafenib
PLX-4032
Ro-5185426
RG-7204",Y,272,www.icoa.fr/pkidb/static/img/mol/Vemurafenib.svg
Verosudil,nan,2,Aerie Pharmaceutical,NaN,NaN,nan,0,327.1,2.8,65.2,4,2,4,nan,nan,,"Smiles=CN(C)C(c1ccsc1)C(=O)Nc2ccc3c(c2)cc[nH]c3=O
InChiKey=VDYRZXYYQMMFJW-UHFFFAOYSA-N",nan,nan,Racemic Mixture,"Verosudil
AR-12286",,,www.icoa.fr/pkidb/static/img/mol/Verosudil.svg
Vistusertib,nan,2,Astrazeneca,NaN,NaN,nan,0,462.2,2.5,92.7,8,1,4,nan,MTOR,Atypical,"Smiles=C[C@H]1COCCN1c2c3ccc(nc3nc(n2)N4CCOC[C@@H]4C)c5cccc(c5)C(=O)NC
InChiKey=JUSFANSTBFGBAF-IRXDYDNUSA-N",nan,nan,Single Stereoisomer,"AZD-2014
AZD2014
Vistusertib",,,www.icoa.fr/pkidb/static/img/mol/Vistusertib.svg
Volasertib,nan,3,Boehringer Ingelheim,'IBI',3fc2 5v67 5vbr,1,1,618.4,4.3,106.2,9,2,10,nan,PLK1,Other,"Smiles=CC[C@H]1N(c2nc(ncc2N(C1=O)C)Nc3c(cc(cc3)C(=O)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6)OC)C(C)C
InChiKey=SXNJFOWDRLKDSF-STROYTFGSA-N",nan,nan,Single Stereoisomer,"BI-6727
Volasertib",,,www.icoa.fr/pkidb/static/img/mol/Volasertib.svg
Voruciclib,nan,2,Piramal Enterprises,NaN,NaN,nan,0,469.1,4.3,94.1,6,3,3,nan,CDK4,CMGC,"Smiles=CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccc(cc4Cl)C(F)(F)F)O)O
InChiKey=MRPGRAKIAJJGMM-OCCSQVGLSA-N",nan,nan,Single Stereoisomer,,,,www.icoa.fr/pkidb/static/img/mol/Voruciclib.svg
Voxtalisib,nan,2,Sanofi,NaN,NaN,nan,0,270.1,1.1,102.5,6,2,2,nan,"PIK3CA
MTOR",Atypical,"Smiles=CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C
InChiKey=RGHYDLZMTYDBDT-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"SAR-245409
Voxtalisib
XL-765",,,www.icoa.fr/pkidb/static/img/mol/Voxtalisib.svg
Zanubrutinib,nan,4,BeiGene,NaN,NaN,nan,0,471.2,4.2,102.5,6,2,6,"Zanubrutinib (BGB-3111) is a potent, selective and and irreversible BTK inhibitor that is being investigated for clinical utility in the treatment of hematological cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [1-2].",nan,,"Smiles=C=CC(=O)N1CCC(CC1)C2CCNc3n2nc(c3C(=O)N)c4ccc(cc4)Oc5ccccc5
InChiKey=RNOAOAWBMHREKO-UHFFFAOYSA-N",2019,nan,nan,"BGB-3111
ZANUBRUTINIB",Y,,www.icoa.fr/pkidb/static/img/mol/Zanubrutinib.svg
(*) indicates that the target is not a kinase,,,,,,,,,,,,,,,,,,,,,,,,
